Free CME from PeerView


Continuing Pharmacy Education (CPE) Activities

Erika Hamilton, MD
Credits: 1.0 CME / MOC / NCPD / CPE / AAPA / IPCE
PVI, PeerView Institute for Medical Education
Simplifying the Complicated: An Algorithmic Guide for Clinical Decision-Making in HR+, HER2- EBC and MBC

Simplifying the Complicated: An Algorithmic Guide for Clinical Decision-Making in HR+, HER2- EBC and MBC

Start

Simplifying the Complicated: An Algorithmic Guide for Clinical Decision-Making in HR+, HER2- EBC and MBC

Media: Enduring Material
Activity Release Date: January 18, 2024
Activity Expiration Date: February 17, 2025
Time to Complete Activity: 60 minutes

Activity Description

Despite their established role in the treatment of HR+, HER2- metastatic breast cancer (MBC) and accumulating evidence supporting their adjuvant use in HR+, HER2- early breast cancer (EBC), questions still surround CDK4/6 inhibitors and their use. While these agents were historically thought to be largely similar and interchangeable, evolving data from clinical and translational studies have shown that CDK4/6 inhibitors are not the same. They have key differences in their chemical, biologic, pharmacologic, and clinical features and different toxicity profiles, despite all being orally bioavailable. Therefore, we must re-evaluate how we approach CDK4/6 inhibitors and integrate them into individualized treatment plans for patients throughout the disease continuum, as well as consider what that looks like in the real-world setting and how to make the most of them and their distinct properties in the frontline setting and beyond?

In this activity, based on a recent live virtual workshop, learners receive an in-depth, expert assessment of CDK4/6 inhibitors in HR+, HER2- EBC and MBC, which provides the foundation for case-based discussions and tool-based demonstrations of algorithmic decision aids designed to guide risk assessment, candidate selection for therapy, and the optimal delivery of treatment to reduce the risk of recurrence in individuals with HR+, HER2- EBC before transitioning to HR+, HER2- MBC to demonstrate patient evaluation, identify factors for prognostication, and model treatment planning, selection, and sequencing throughout the advance disease continuum. Additionally, the panel shares strategies to mitigate and manage common adverse reactions associated with CDK4/6 inhibitors to improve treatment adherence and persistence.

Target Audience

This activity has been designed to meet the educational needs of medical oncologists, advanced practice clinicians, nurses, pharmacists, and other healthcare professionals involved in the care of patients with early and metastatic breast cancer.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Identify patients with HR+, HER2- EBC and MBC via thorough assessment of clinical, pathologic, genomic, and other relevant factors
  • Design individualized treatment protocols integrating CDK4/6 inhibitor therapy for patients with HR+, HER2- EBC and MBC based on the latest evidence, guidelines, and tumor/disease characteristics
  • Develop team-based strategies to achieve optimal treatment adherence/persistence and prevention/mitigation of AEs associated with different CDK4/6 inhibitors in the treatment of HR+, HER2- EBC and MBC

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Erika Hamilton, MD
Chair, Breast Executive Committee
Director, Breast Cancer Research Program
Sarah Cannon Research Institute
Nashville, Tennessee

Erika Hamilton, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Arcus Biosciences, Inc.; Arvinas, Inc.; AstraZeneca; Daiichi Sankyo, Inc.; Deciphera Pharmaceuticals, Inc.; Ellipses Pharma; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Greenwich LifeSciences, Inc.; iTeos Therapeutics; Janssen Pharmaceuticals, Inc.; Lilly; Loxo Oncology; Mersana Therapeutics; Novartis Pharmaceuticals Corporation; Orum Therapeutics; Pfizer; Relay Therapeutics; Seagen Inc.; and Verascity Science (all paid to institution).
Grant/Research Support from AbbVie Inc.; Accutar Biotechnology Inc; Acerta Pharma; ADC Therapeutics SA; Akeso Biopharma Co., Ltd.; Amgen Inc.; Aravive; Artios Pharma; Arvinas, Inc.; AstraZeneca; AtlasMedx, Inc.; BeiGene, Inc.; Black Diamond Therapeutics, Inc.; Bliss Biopharmaceutical (Hangzhou) Co., Ltd.; Boehringer Ingelheim Pharmaceuticals, Inc.; Cascadian Therapeutics; Clovis Oncology; Compugen; Cullinan Oncology, Inc.; Curis, Inc.; CytomX Therapeutics, Inc.; Daiichi Sankyo, Inc.; Dana-Farber Cancer Institute; Dantari; Deciphera Pharmaceuticals, Inc.; Duality Biologics; eFFECTOR Therapeutics, Inc.; Ellipses Pharma; Elucida Oncology, Inc.; EMD Serono, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; FUJIFILM Pharmaceuticals U.S.A., Inc.; G1 Therapeutics, Inc.; H3 Biomedicine Inc.; Harpoon Therapeutics; HUTCHMED (China) Limited; ImmunoGen, Inc.; Immunomedics, Inc.; Incyte; Infinity Pharmaceuticals, Inc.; InvestisBio; Jacobio Pharmaceuticals Group Co., Ltd.; K-Group Beta, Inc.; Karyopharm; Lilly; Loxo Oncology; Lycera; MabSpace Biosciences Co., Ltd.; MacroGenics, Inc.; MedImmune, LLC; Mersana Therapeutics; Merus; Millennium Pharmaceuticals, Inc.; Molecular Templates, Inc.; Novartis Pharmaceuticals Corporation; Nucana; Olema Oncology; OncoMed Pharmaceuticals, Inc.; Onconova Therapeutics; Oncothyreon; ORIC Pharmaceuticals, Inc.; Orinove Inc.; Pfizer; PharmaMar; Pieris Pharmaceuticals, Inc.; Pionyr Immunotherapeutics; Plexxikon; Radius Health, Inc.; Regeneron Pharmaceuticals Inc.; Relay Therapeutics; Repertoire Immune Medicines; Rgenix Inc.; Seagen Inc.; Sermonix Pharmaceuticals; Shattuck Labs Inc.; Stemcentrx, Inc.; Sutro Biopharma, Inc.; Syndax; Syros Pharmaceuticals, Inc.; Taiho Oncology, Inc.; TapImmune Inc; TESARO, Inc.; Tolmar Pharmaceuticals, Inc.; Torque Therapeutics, Inc.; Treadwell Therapeutics; Verastem, Inc.; Vincerx Pharma; zenithepigenetics; and Zymeworks Inc. (all paid to institution).

Faculty/Planner
Komal Jhaveri, MD, FACP
Patricia and James Cayne Chair for Junior Faculty
Associate Attending
Breast Medicine Service and Early Drug Development Service
Section Head, Endocrine Therapy Research Program
Clinical Director, Early Drug Development Service
Department of Medicine
Memorial Sloan Kettering Cancer Center/Evelyn H. Lauder Breast and Imaging Center
New York, New York

Komal Jhaveri, MD, FACP, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; AstraZeneca; Blueprint Medicines; Bristol Myers Squibb; Daiichi Sankyo, Inc.; Eisai Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Jounce Therapeutics, Inc.; Lilly/Loxo Oncology; Menarini Group/Stemline Therapeutics; Novartis Pharmaceuticals Corporation; Pfizer; Scorpion Therapeutics; Seattle Genetics, Inc. (Seagen Inc.); Sun Pharma Advanced Research Company; and Taiho Oncology, Inc.
Grant/Research Support from ADC Therapeutics SA; AstraZeneca; Blueprint Medicines; Debiopharm; Genentech, Inc.; Gilead Sciences, Inc.; Lilly; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Novita Pharmaceuticals, Inc.; Pfizer; Puma Biotechnology, Inc.; Scorpion Therapeutics; and Zymeworks Inc.

Faculty/Planner
Professor Stephen Johnston, MA, PhD
Professor of Breast Cancer Medicine & Head of Medical Oncology
Consultant Medical Oncologist & Head of The Breast Unit
The Royal Marsden NHS Foundation Trust & The Institute of Cancer Research
Chelsea, London, United Kingdom

Professor Stephen Johnston, MA, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Lilly; Novartis Pharmaceuticals Corporation; Pfizer; Puma Biotechnology, Inc.; and Sanofi.
Grant/Research Support from AstraZeneca; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Lilly; Novartis Pharmaceuticals Corporation; Pfizer; and Puma Biotechnology, Inc.
Speakers Bureau participant with AstraZeneca; Eisai Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; and Pfizer.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by an educational grant from Lilly.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-24-015-H01-P
Type of Activity: Application

Physician Assistants

AAPA PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 2/17/2025. PAs should only claim credit commensurate with the extent of their participation.

Interprofessional Continuing Education (IPCE) Statement

IPCE This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD/CPE/AAPA/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2024, PeerView

Simplifying the Complicated: An Algorithmic Guide for Clinical Decision-Making in HR+, HER2- EBC and MBC

Media: Enduring Material
Activity Release Date: January 18, 2024
Activity Expiration Date: February 17, 2025
Time to Complete Activity: 60 minutes

Activity Description

Despite their established role in the treatment of HR+, HER2- metastatic breast cancer (MBC) and accumulating evidence supporting their adjuvant use in HR+, HER2- early breast cancer (EBC), questions still surround CDK4/6 inhibitors and their use. While these agents were historically thought to be largely similar and interchangeable, evolving data from clinical and translational studies have shown that CDK4/6 inhibitors are not the same. They have key differences in their chemical, biologic, pharmacologic, and clinical features and different toxicity profiles, despite all being orally bioavailable. Therefore, we must re-evaluate how we approach CDK4/6 inhibitors and integrate them into individualized treatment plans for patients throughout the disease continuum, as well as consider what that looks like in the real-world setting and how to make the most of them and their distinct properties in the frontline setting and beyond?

In this activity, based on a recent live virtual workshop, learners receive an in-depth, expert assessment of CDK4/6 inhibitors in HR+, HER2- EBC and MBC, which provides the foundation for case-based discussions and tool-based demonstrations of algorithmic decision aids designed to guide risk assessment, candidate selection for therapy, and the optimal delivery of treatment to reduce the risk of recurrence in individuals with HR+, HER2- EBC before transitioning to HR+, HER2- MBC to demonstrate patient evaluation, identify factors for prognostication, and model treatment planning, selection, and sequencing throughout the advance disease continuum. Additionally, the panel shares strategies to mitigate and manage common adverse reactions associated with CDK4/6 inhibitors to improve treatment adherence and persistence.

Target Audience

This activity has been designed to meet the educational needs of medical oncologists, advanced practice clinicians, nurses, pharmacists, and other healthcare professionals involved in the care of patients with early and metastatic breast cancer.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Identify patients with HR+, HER2- EBC and MBC via thorough assessment of clinical, pathologic, genomic, and other relevant factors
  • Design individualized treatment protocols integrating CDK4/6 inhibitor therapy for patients with HR+, HER2- EBC and MBC based on the latest evidence, guidelines, and tumor/disease characteristics
  • Develop team-based strategies to achieve optimal treatment adherence/persistence and prevention/mitigation of AEs associated with different CDK4/6 inhibitors in the treatment of HR+, HER2- EBC and MBC

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Erika Hamilton, MD
Chair, Breast Executive Committee
Director, Breast Cancer Research Program
Sarah Cannon Research Institute
Nashville, Tennessee

Erika Hamilton, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Arcus Biosciences, Inc.; Arvinas, Inc.; AstraZeneca; Daiichi Sankyo, Inc.; Deciphera Pharmaceuticals, Inc.; Ellipses Pharma; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Greenwich LifeSciences, Inc.; iTeos Therapeutics; Janssen Pharmaceuticals, Inc.; Lilly; Loxo Oncology; Mersana Therapeutics; Novartis Pharmaceuticals Corporation; Orum Therapeutics; Pfizer; Relay Therapeutics; Seagen Inc.; and Verascity Science (all paid to institution).
Grant/Research Support from AbbVie Inc.; Accutar Biotechnology Inc; Acerta Pharma; ADC Therapeutics SA; Akeso Biopharma Co., Ltd.; Amgen Inc.; Aravive; Artios Pharma; Arvinas, Inc.; AstraZeneca; AtlasMedx, Inc.; BeiGene, Inc.; Black Diamond Therapeutics, Inc.; Bliss Biopharmaceutical (Hangzhou) Co., Ltd.; Boehringer Ingelheim Pharmaceuticals, Inc.; Cascadian Therapeutics; Clovis Oncology; Compugen; Cullinan Oncology, Inc.; Curis, Inc.; CytomX Therapeutics, Inc.; Daiichi Sankyo, Inc.; Dana-Farber Cancer Institute; Dantari; Deciphera Pharmaceuticals, Inc.; Duality Biologics; eFFECTOR Therapeutics, Inc.; Ellipses Pharma; Elucida Oncology, Inc.; EMD Serono, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; FUJIFILM Pharmaceuticals U.S.A., Inc.; G1 Therapeutics, Inc.; H3 Biomedicine Inc.; Harpoon Therapeutics; HUTCHMED (China) Limited; ImmunoGen, Inc.; Immunomedics, Inc.; Incyte; Infinity Pharmaceuticals, Inc.; InvestisBio; Jacobio Pharmaceuticals Group Co., Ltd.; K-Group Beta, Inc.; Karyopharm; Lilly; Loxo Oncology; Lycera; MabSpace Biosciences Co., Ltd.; MacroGenics, Inc.; MedImmune, LLC; Mersana Therapeutics; Merus; Millennium Pharmaceuticals, Inc.; Molecular Templates, Inc.; Novartis Pharmaceuticals Corporation; Nucana; Olema Oncology; OncoMed Pharmaceuticals, Inc.; Onconova Therapeutics; Oncothyreon; ORIC Pharmaceuticals, Inc.; Orinove Inc.; Pfizer; PharmaMar; Pieris Pharmaceuticals, Inc.; Pionyr Immunotherapeutics; Plexxikon; Radius Health, Inc.; Regeneron Pharmaceuticals Inc.; Relay Therapeutics; Repertoire Immune Medicines; Rgenix Inc.; Seagen Inc.; Sermonix Pharmaceuticals; Shattuck Labs Inc.; Stemcentrx, Inc.; Sutro Biopharma, Inc.; Syndax; Syros Pharmaceuticals, Inc.; Taiho Oncology, Inc.; TapImmune Inc; TESARO, Inc.; Tolmar Pharmaceuticals, Inc.; Torque Therapeutics, Inc.; Treadwell Therapeutics; Verastem, Inc.; Vincerx Pharma; zenithepigenetics; and Zymeworks Inc. (all paid to institution).

Faculty/Planner
Komal Jhaveri, MD, FACP
Patricia and James Cayne Chair for Junior Faculty
Associate Attending
Breast Medicine Service and Early Drug Development Service
Section Head, Endocrine Therapy Research Program
Clinical Director, Early Drug Development Service
Department of Medicine
Memorial Sloan Kettering Cancer Center/Evelyn H. Lauder Breast and Imaging Center
New York, New York

Komal Jhaveri, MD, FACP, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; AstraZeneca; Blueprint Medicines; Bristol Myers Squibb; Daiichi Sankyo, Inc.; Eisai Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Jounce Therapeutics, Inc.; Lilly/Loxo Oncology; Menarini Group/Stemline Therapeutics; Novartis Pharmaceuticals Corporation; Pfizer; Scorpion Therapeutics; Seattle Genetics, Inc. (Seagen Inc.); Sun Pharma Advanced Research Company; and Taiho Oncology, Inc.
Grant/Research Support from ADC Therapeutics SA; AstraZeneca; Blueprint Medicines; Debiopharm; Genentech, Inc.; Gilead Sciences, Inc.; Lilly; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Novita Pharmaceuticals, Inc.; Pfizer; Puma Biotechnology, Inc.; Scorpion Therapeutics; and Zymeworks Inc.

Faculty/Planner
Professor Stephen Johnston, MA, PhD
Professor of Breast Cancer Medicine & Head of Medical Oncology
Consultant Medical Oncologist & Head of The Breast Unit
The Royal Marsden NHS Foundation Trust & The Institute of Cancer Research
Chelsea, London, United Kingdom

Professor Stephen Johnston, MA, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Lilly; Novartis Pharmaceuticals Corporation; Pfizer; Puma Biotechnology, Inc.; and Sanofi.
Grant/Research Support from AstraZeneca; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Lilly; Novartis Pharmaceuticals Corporation; Pfizer; and Puma Biotechnology, Inc.
Speakers Bureau participant with AstraZeneca; Eisai Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; and Pfizer.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by an educational grant from Lilly.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-24-015-H01-P
Type of Activity: Application

Physician Assistants

AAPA PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 2/17/2025. PAs should only claim credit commensurate with the extent of their participation.

Interprofessional Continuing Education (IPCE) Statement

IPCE This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD/CPE/AAPA/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2024, PeerView

January 18, 2024
Meghan C. Thompson, MD/Catherine C. Coombs, MD
Credits: 1.0 CME / MOC / NCPD / CPE / AAPA / IPCE
PVI, PeerView Institute for Medical Education
From Resistance to Resilience in R/R CLL: Sequencing Strategies for Achieving Effective Continuous Care

From Resistance to Resilience in R/R CLL: Sequencing Strategies for Achieving Effective Continuous Care

Start

 
 

From Resistance to Resilience in R/R CLL: Sequencing Strategies for Achieving Effective Continuous Care


 

Media: Enduring Material

    Activity Release Date: January 17, 2024

    Activity Expiration Date: February 16, 2025

    Time to Complete Activity: 60 minutes


 

Activity Description


 

Can you move from resistance to resilience with BTK inhibitors (BTKi) in relapsed/refractory chronic lymphocytic leukemia (CLL)? Learn how to overcome the well-recognized barriers—including therapeutic intolerance and disease progression—to effective sequential care by joining CLL experts in this case-based educational program. In this activity, developed in collaboration with CLL Society, the experts provide guidance on integrating new sequential BTKi options into everyday clinical practice and share patient scenarios designed to showcase skills that can help overcome medical challenges associated with continuous BTKi therapy over multiple lines of treatment. Don’t miss this opportunity to get back to resilient care with BTKi options in CLL!


 

Target Audience


 

This activity has been designed to meet the educational needs of hematologist-oncologists, NPs, PAs, nurses, pharmacists, and other care team professionals involved in the management of patients with R/R CLL.


 

Educational Objectives


 

Upon completion of this activity, participants should be better able to:


 

  •    
  • Summarize the mechanistic, selectivity, and safety differences among covalent and non-covalent BTKi, including off-target effects, therapeutic intolerance, and mechanisms of BTK resistance

  •    
  • Implement best practices for capturing relevant prognostic factors, disease progression, and therapeutic intolerance to guide treatment planning with BTKi in R/R CLL

  •    
  • Formulate effective sequential treatment plans with BTKi strategies in CLL based on current evidence, prognostic information, and other patient- and disease-specific factors

  •    
  • Employ team-based approaches to address practical aspects of CLL care when using BTKi, including care coordination, formulary planning, patient education, dosing, and management of treatment-related AEs

  •  

 

Disclosure Policy


 

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.


 

Faculty/Planner Disclosures


 

Co-Chair/Planner

    Meghan C. Thompson, MD

    Assistant Attending L1, Leukemia Service

    Memorial Sloan Kettering Cancer Center

    New York, New York


 

Meghan C. Thompson, MD, has a financial interest/relationship or affiliation in the form of:

    Consultant and/or Advisor for AstraZeneca; Lilly/Loxo Oncology, Inc.; and Pharmacyclics LLC/Janssen Pharmaceuticals, Inc.

    Grant/Research Support from AbbVie; AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Genmab; and Nurix Therapeutics. Research funding goes to Institution.

 


 

Co-Chair/Planner

    Catherine C. Coombs, MD

    Associate Clinical Professor

    University of California, Irvine

    Orange, California


 

Catherine C. Coombs, MD, has a financial interest/relationship or affiliation in the form of:

    Consultant and/or Advisor for AbbVie Inc.; Allogene Therapeutics; AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Lilly; MEI Pharma, Inc.; Mingsight Pharmaceuticals, Inc.; and Octapharma USA, Inc.

    Grant/Research Support from Lilly.

    Speaker for AbbVie Inc.; AstraZeneca; BeiGene, Inc.; and Genentech, Inc.

 


 

Planning Committee and Reviewer Disclosures


 

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.


 

Accreditation, Support, and Credit


    
    
 
   
     
       
       
     
   
 
JAP In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and CLL Society. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 

Support


 

This activity is supported by an educational grant from Lilly.


 

Physicians


 

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


 

The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).


 

MOC Statement


 
   
     
       
       
     
   
 
MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points  and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

 

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).


 

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.


 

Nurses


 

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.


 

Pharmacists


 

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.

    Universal Activity Number: JA4008289-9999-24-011-H01-P

    Type of Activity: Application


 

Physician Assistants


 
   
     
       
       
     
   
 
AAPA PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 2/16/2025. PAs should only claim credit commensurate with the extent of their participation.

 

Interprofessional Continuing Education (IPCE) Statement


 
   
     
       
       
     
   
 
IPCE This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

 

Method of Participation


 

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

   

    A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

   

    If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD), and a score of 75% or higher is needed to obtain MOC/CC credit.

   

    For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

   

    For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.


 

Disclosure of Unlabeled Use


 

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


 

About This CME/MOC/NCPD/CPE/AAPA/IPCE Activity


 

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.


 

Copyright © 2000-2024, PeerView



 
 

From Resistance to Resilience in R/R CLL: Sequencing Strategies for Achieving Effective Continuous Care


 

Media: Enduring Material

    Activity Release Date: January 17, 2024

    Activity Expiration Date: February 16, 2025

    Time to Complete Activity: 60 minutes


 

Activity Description


 

Can you move from resistance to resilience with BTK inhibitors (BTKi) in relapsed/refractory chronic lymphocytic leukemia (CLL)? Learn how to overcome the well-recognized barriers—including therapeutic intolerance and disease progression—to effective sequential care by joining CLL experts in this case-based educational program. In this activity, developed in collaboration with CLL Society, the experts provide guidance on integrating new sequential BTKi options into everyday clinical practice and share patient scenarios designed to showcase skills that can help overcome medical challenges associated with continuous BTKi therapy over multiple lines of treatment. Don’t miss this opportunity to get back to resilient care with BTKi options in CLL!


 

Target Audience


 

This activity has been designed to meet the educational needs of hematologist-oncologists, NPs, PAs, nurses, pharmacists, and other care team professionals involved in the management of patients with R/R CLL.


 

Educational Objectives


 

Upon completion of this activity, participants should be better able to:


 

  •    
  • Summarize the mechanistic, selectivity, and safety differences among covalent and non-covalent BTKi, including off-target effects, therapeutic intolerance, and mechanisms of BTK resistance

  •    
  • Implement best practices for capturing relevant prognostic factors, disease progression, and therapeutic intolerance to guide treatment planning with BTKi in R/R CLL

  •    
  • Formulate effective sequential treatment plans with BTKi strategies in CLL based on current evidence, prognostic information, and other patient- and disease-specific factors

  •    
  • Employ team-based approaches to address practical aspects of CLL care when using BTKi, including care coordination, formulary planning, patient education, dosing, and management of treatment-related AEs

  •  

 

Disclosure Policy


 

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.


 

Faculty/Planner Disclosures


 

Co-Chair/Planner

    Meghan C. Thompson, MD

    Assistant Attending L1, Leukemia Service

    Memorial Sloan Kettering Cancer Center

    New York, New York


 

Meghan C. Thompson, MD, has a financial interest/relationship or affiliation in the form of:

    Consultant and/or Advisor for AstraZeneca; Lilly/Loxo Oncology, Inc.; and Pharmacyclics LLC/Janssen Pharmaceuticals, Inc.

    Grant/Research Support from AbbVie; AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Genmab; and Nurix Therapeutics. Research funding goes to Institution.

 


 

Co-Chair/Planner

    Catherine C. Coombs, MD

    Associate Clinical Professor

    University of California, Irvine

    Orange, California


 

Catherine C. Coombs, MD, has a financial interest/relationship or affiliation in the form of:

    Consultant and/or Advisor for AbbVie Inc.; Allogene Therapeutics; AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Lilly; MEI Pharma, Inc.; Mingsight Pharmaceuticals, Inc.; and Octapharma USA, Inc.

    Grant/Research Support from Lilly.

    Speaker for AbbVie Inc.; AstraZeneca; BeiGene, Inc.; and Genentech, Inc.

 


 

Planning Committee and Reviewer Disclosures


 

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.


 

Accreditation, Support, and Credit


    
    
 
   
     
       
       
     
   
 
JAP In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and CLL Society. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 

Support


 

This activity is supported by an educational grant from Lilly.


 

Physicians


 

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


 

The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).


 

MOC Statement


 
   
     
       
       
     
   
 
MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points  and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

 

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).


 

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.


 

Nurses


 

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.


 

Pharmacists


 

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.

    Universal Activity Number: JA4008289-9999-24-011-H01-P

    Type of Activity: Application


 

Physician Assistants


 
   
     
       
       
     
   
 
AAPA PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 2/16/2025. PAs should only claim credit commensurate with the extent of their participation.

 

Interprofessional Continuing Education (IPCE) Statement


 
   
     
       
       
     
   
 
IPCE This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

 

Method of Participation


 

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

   

    A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

   

    If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD), and a score of 75% or higher is needed to obtain MOC/CC credit.

   

    For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

   

    For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.


 

Disclosure of Unlabeled Use


 

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


 

About This CME/MOC/NCPD/CPE/AAPA/IPCE Activity


 

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.


 

Copyright © 2000-2024, PeerView


January 17, 2024
John L. Marshall, MD
Credits: 0.75 CME / MOC / CC / NCPD / CPE / AAPA / IPCE
PVI, PeerView Institute for Medical Education
Hitting the Benchmarks in mCRC: A Precision Medicine Quality Initiative for the Care Team

Hitting the Benchmarks in mCRC: A Precision Medicine Quality Initiative for the Care Team

Start

 
 

Hitting the Benchmarks in mCRC: A Precision Medicine Quality Initiative for the Care Team


 

Media: Enduring Material

    Activity Release Date: January 12, 2024

    Activity Expiration Date: January 11, 2025

    Time to Complete Activity: 45 minutes


 

Activity Description


 

In this modern era of precision oncology, several therapies targeting pathways that contribute to metastatic colorectal cancer (mCRC) pathogenesis have emerged, including therapies targeting EGFR, VEGF, and the BRAF kinase. Selecting upfront and sequential treatment by considering patient- and tumor-related factors is key to informed shared decision-making and maximizing clinical benefit for patients. This activity features an expert overview of the significance of tumor sidedness in patients with mCRC, how to effectively utilize molecular testing to determine an appropriate course of treatment, and sequencing strategies across the mCRC spectrum.


 

Target Audience


 

This activity has been designed to meet the educational needs of oncologists, pathologists, radiologists, oncology nurses, nurse practitioners, physician assistants, pharmacists, and other clinicians involved in the care of patients with mCRC.


 

Educational Objectives


 

Upon completion of this activity, participants should be better able to:


 

  •    
  • Implement tumor genotyping and evaluation of tumor sidedness at mCRC diagnosis based on current evidence, guideline recommendations, and an understanding of the mechanistic rationale

  •    
  • Formulate personalized mCRC treatment plans with targeted therapies that are driven by molecular findings and primary tumor localization and supported by the latest evidence and guideline recommendations using a team-based approach

  •  

 

Disclosure Policy


 

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.


 

Faculty/Planner Disclosures


 

Chair/Planner

    John L. Marshall, MD

    Director, The Ruesch Center for the Cure of GI Cancers

    Frederick P. Smith Endowed Chair

    Chief Medical Officer

    Lombardi Comprehensive Cancer Center

    Georgetown University Medical Center

    Washington, District of Columbia


 

John L. Marshall, MD, has a financial interest/relationship or affiliation in the form of:

    Consultant and/or Advisor for Arcos; AstraZeneca; Bayer Corporation; Caris Life Sciences; Merck & Co., Inc.; Oradose; Pfizer; Seagen Inc.; Taiho Oncology, Inc.; Takeda Pharmaceutical Company Limited; and Zcurex.

    Grant/Research Support from Arcos; AstraZeneca; Bayer Corporation; Caris Life Sciences; Merck & Co., Inc.; Oradose; Pfizer; Seagen Inc.; Taiho Oncology, Inc.; Takeda Pharmaceutical Company Limited; and Zcurex.

    Other Financial or Material Support Executive role for Indivumed GmbH.

 


 

Planning Committee and Reviewer Disclosures


 

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.


 

Accreditation, Support, and Credit


    
 
   
     
       
       
     
   
 
JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 

Support


 

This activity is supported by an educational grant from Lilly.


 

Physicians


 

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


 

The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).


 

MOC Statement


 
   
     
       
       
     
   
 
MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points  and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

 

Continuing Certification Statement


 
   
     
       
       
     
   
 
ABPath The activity titled “Hitting the Benchmarks in mCRC: A Precision Medicine Quality Initiative for the Care Team” has been registered to offer 0.75 Lifelong Learning credit in the American Board of Pathology’s (ABPath) Continuing Certification program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABPath Continuing Certification credit.

 

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).


 

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.


 

Nurses


 

Successful completion of this nursing continuing professional education activity will be awarded 0.75 contact hour(s) and 0.5 contact hour(s) in the area of pharmacology.


 

Pharmacists


 

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 0.75 contact hours (0.075 CEUs) of the Accreditation Council for Pharmacy Education.

    Universal Activity Number: JA4008289-0000-23-066-H01-P

    Type of Activity: Application


 

Physician Assistants


 
   
     
       
       
     
   
 
AAPA PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credits. Approval is valid until 1/11/2025. PAs should only claim credit commensurate with the extent of their participation.

 

Interprofessional Continuing Education (IPCE) Statement


 
   
     
       
       
     
   
 
IPCE This activity was planned by and for the healthcare team, and learners will receive 0.75 Interprofessional Continuing Education (IPCE) credit for learning and change.

 

Method of Participation


 

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

   

    A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

   

    If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is needed to obtain MOC/CC credit.

   

    For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

   

    For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.


 

Disclosure of Unlabeled Use


 

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


 

About This CME/MOC/CC/NCPD/CPE/AAPA/IPCE Activity


 

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.


 

Copyright © 2000-2024, PeerView



 
 

Hitting the Benchmarks in mCRC: A Precision Medicine Quality Initiative for the Care Team


 

Media: Enduring Material

    Activity Release Date: January 12, 2024

    Activity Expiration Date: January 11, 2025

    Time to Complete Activity: 45 minutes


 

Activity Description


 

In this modern era of precision oncology, several therapies targeting pathways that contribute to metastatic colorectal cancer (mCRC) pathogenesis have emerged, including therapies targeting EGFR, VEGF, and the BRAF kinase. Selecting upfront and sequential treatment by considering patient- and tumor-related factors is key to informed shared decision-making and maximizing clinical benefit for patients. This activity features an expert overview of the significance of tumor sidedness in patients with mCRC, how to effectively utilize molecular testing to determine an appropriate course of treatment, and sequencing strategies across the mCRC spectrum.


 

Target Audience


 

This activity has been designed to meet the educational needs of oncologists, pathologists, radiologists, oncology nurses, nurse practitioners, physician assistants, pharmacists, and other clinicians involved in the care of patients with mCRC.


 

Educational Objectives


 

Upon completion of this activity, participants should be better able to:


 

  •    
  • Implement tumor genotyping and evaluation of tumor sidedness at mCRC diagnosis based on current evidence, guideline recommendations, and an understanding of the mechanistic rationale

  •    
  • Formulate personalized mCRC treatment plans with targeted therapies that are driven by molecular findings and primary tumor localization and supported by the latest evidence and guideline recommendations using a team-based approach

  •  

 

Disclosure Policy


 

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.


 

Faculty/Planner Disclosures


 

Chair/Planner

    John L. Marshall, MD

    Director, The Ruesch Center for the Cure of GI Cancers

    Frederick P. Smith Endowed Chair

    Chief Medical Officer

    Lombardi Comprehensive Cancer Center

    Georgetown University Medical Center

    Washington, District of Columbia


 

John L. Marshall, MD, has a financial interest/relationship or affiliation in the form of:

    Consultant and/or Advisor for Arcos; AstraZeneca; Bayer Corporation; Caris Life Sciences; Merck & Co., Inc.; Oradose; Pfizer; Seagen Inc.; Taiho Oncology, Inc.; Takeda Pharmaceutical Company Limited; and Zcurex.

    Grant/Research Support from Arcos; AstraZeneca; Bayer Corporation; Caris Life Sciences; Merck & Co., Inc.; Oradose; Pfizer; Seagen Inc.; Taiho Oncology, Inc.; Takeda Pharmaceutical Company Limited; and Zcurex.

    Other Financial or Material Support Executive role for Indivumed GmbH.

 


 

Planning Committee and Reviewer Disclosures


 

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.


 

Accreditation, Support, and Credit


    
 
   
     
       
       
     
   
 
JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 

Support


 

This activity is supported by an educational grant from Lilly.


 

Physicians


 

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


 

The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).


 

MOC Statement


 
   
     
       
       
     
   
 
MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points  and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

 

Continuing Certification Statement


 
   
     
       
       
     
   
 
ABPath The activity titled “Hitting the Benchmarks in mCRC: A Precision Medicine Quality Initiative for the Care Team” has been registered to offer 0.75 Lifelong Learning credit in the American Board of Pathology’s (ABPath) Continuing Certification program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABPath Continuing Certification credit.

 

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).


 

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.


 

Nurses


 

Successful completion of this nursing continuing professional education activity will be awarded 0.75 contact hour(s) and 0.5 contact hour(s) in the area of pharmacology.


 

Pharmacists


 

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 0.75 contact hours (0.075 CEUs) of the Accreditation Council for Pharmacy Education.

    Universal Activity Number: JA4008289-0000-23-066-H01-P

    Type of Activity: Application


 

Physician Assistants


 
   
     
       
       
     
   
 
AAPA PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credits. Approval is valid until 1/11/2025. PAs should only claim credit commensurate with the extent of their participation.

 

Interprofessional Continuing Education (IPCE) Statement


 
   
     
       
       
     
   
 
IPCE This activity was planned by and for the healthcare team, and learners will receive 0.75 Interprofessional Continuing Education (IPCE) credit for learning and change.

 

Method of Participation


 

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

   

    A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

   

    If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is needed to obtain MOC/CC credit.

   

    For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

   

    For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.


 

Disclosure of Unlabeled Use


 

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


 

About This CME/MOC/CC/NCPD/CPE/AAPA/IPCE Activity


 

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.


 

Copyright © 2000-2024, PeerView


January 12, 2024
Joyce O’Shaughnessy, MD
Credits: 1.0 CME / MOC / NCPD / CPE / AAPA / IPCE
PVI, PeerView Institute for Medical Education
Custom Care Compass: Mastering Multifactorial Clinical Decision-Making in High-Risk HR+, HER2- MBC

Custom Care Compass: Mastering Multifactorial Clinical Decision-Making in High-Risk HR+, HER2- MBC

Start

 
 

Custom Care Compass: Mastering Multifactorial Clinical Decision-Making in High-Risk HR+, HER2- MBC


 

Media: Enduring Material

    Activity Release Date: January 10, 2024

    Activity Expiration Date: February 9, 2025

    Time to Complete Activity: 60 minutes


 

Activity Description


 

The standard of care for patients with HR+, HER2- locally advanced unresectable or metastatic breast cancer (MBC) in the first-line setting involves endocrine therapy in combination with a CDK4/6 inhibitor. However, questions persist regarding the optimal use of each CDK4/6 inhibitor in first- and later-line settings. Ongoing research, fortunately, is providing new insights into the use of CDK4/6 inhibitors. Additionally, a number of investigational therapies with the potential to change clinical practice are showing great promise, with some recently approved in the metastatic setting. These investigational therapies include novel oral SERDs, ATK inhibition, and antibody–drug conjugates, such as those targeting HER2 and TROP2. With these therapies proving their clinical potential, it is essential to learn how to best integrate them into the current treatment arsenal. Furthermore, various patient- and disease-related factors such as age, HR status, metastatic sites, visceral involvement, endocrine resistance, tumor grade, disease-free interval, and molecular profile must be considered for optimal individualized therapy as well. In this PeerView Live virtual workshop, presented through a case-based framework, leading experts review the latest clinical evidence and provide practical strategies on navigating the complexities of clinical decision-making and selection and sequencing of therapies. The panel also addresses the nuances of treatment delivery and best practices for mitigating and managing adverse events associated with CDK4/6 inhibitors to help patients with HR+, HER2- MBC achieve the best possible outcomes.


 

Target Audience


 

This activity has been designed to meet the educational needs of oncologists, advanced practice clinicians, nurses, pharmacists, and other healthcare professionals involved in the care of patients with HR+, HER2- MBC.


 

Educational Objectives


 

Upon completion of this activity, participants should be better able to:


 

  •    
  • Evaluate the latest efficacy and safety data supporting the use of CDK4/6 inhibitors, as well as new and emerging treatment options for patients with HR+, HER2- MBC, considering their evolving roles in clinical practice

  •    
  • Develop individualized treatment plans that integrate CDK4/6 inhibitor therapy for patients with HR+, HER2- MBC, based on the latest evidence, guidelines, and assessment of drug-, tumor/disease-, and patient-related factors

  •    
  • Implement team-based strategies to achieve optimal treatment adherence and persistence, as well as prevent and mitigate adverse events associated with different CDK4/6 inhibitors in the management of HR+, HER2- MBC

  •  

 

Disclosure Policy


 

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.


 

Faculty/Planner Disclosures


 

Chair/Planner

    Joyce O’Shaughnessy, MD

    Celebrating Women Chair in Breast Cancer Research

    Baylor University Medical Center

    Director, Breast Cancer Research Program

    Texas Oncology

    US Oncology

    Dallas, Texas


 

Joyce O’Shaughnessy, MD, has a financial interest/relationship or affiliation in the form of:

    Consultant and/or Advisor for AbbVie Inc.; Agendia; Amgen Inc.; Aptitude Health; AstraZeneca; Bayer HealthCare Pharmaceuticals, Inc.; Bristol Myers Squibb; Celgene Corporation; Daiichi Sankyo, Inc.; Duality Biologics; Eisai Inc.; F. Hoffmann-La Roche Ltd.; G1 Therapeutics, Inc.; Genentech, Inc.; Gilead Sciences, Inc.; GRAIL, Inc.; Halozyme, Inc.; Heron Therapeutics, Inc.; Immunomedics, Inc.; Ipsen Biopharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Myriad Genetics, Inc.; Nektar; Novartis Pharmaceuticals Corporation; Ontada LLC; Pfizer; Pharmacyclics LLC; Pierre Fabre group; prIME Oncology; Puma Biotechnology, Inc.; Samsung Bioepis; Sanofi; Scorpion Therapeutics, Inc.; Seagen Inc.; Stemline Therapeutics, Inc./The Menarini Group; Syndax Pharmaceuticals Inc.; Synthon; Taiho Oncology, Inc.; and Takeda Pharmaceutical Company Limited.

 


 

Faculty/Planner

    Sara M. Tolaney, MD, MPH

    Chief, Division of Breast Oncology

    Associate Director

    Susan F. Smith Center for Women’s Cancers

    Senior Physician

    Dana-Farber Cancer Institute

    Associate Professor of Medicine

    Harvard Medical School

    Boston, Massachusetts


 

Sara M. Tolaney, MD, MPH, has a financial interest/relationship or affiliation in the form of:

    Consultant and/or Advisor for 4D pharma plc; Aadi Bioscience, Inc.; ARC Therapeutics; Artios Pharma; AstraZeneca; Bayer HealthCare Pharmaceuticals, Inc.; BeyondSpring Pharmaceuticals Inc.; Blueprint Medicines; Bristol Myers Squibb; CytomX Therapeutics, Inc.; Daiichi Sankyo Inc.; eFFECTOR Therapeutics; Eisai Inc.; Exelixis, Inc.; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Gilead Sciences, Inc.; Incyte; Jazz Pharmaceuticals; Lilly; Merck & Co., Inc.; Myovant Sciences Ltd.; Natera; Novartis Pharmaceuticals Corporation; Pfizer; Reveal Genomics; Sanofi; Seattle Genetics, Inc.; Stemline Therapeutics, Inc./The Menarini Group; Systimmune; Tango Therapeutics; Umoja Biopharma; Zentalis; Zetagen; and Zymeworks Inc.

    Grant/Research Support from AstraZeneca; Bristol Myers Squibb; Cyclacel Pharmaceuticals, Inc.; Eisai Inc.; Exelixis, Inc.; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Gilead Sciences, Inc.; Lilly; Merck & Co., Inc.; NanoString Technologies Inc.; Nektar; Novartis Pharmaceuticals Corporation; Pfizer; Sanofi; and Seattle Genetics, Inc.

    Other Financial or Material Support from Steering committee for CytomX Therapeutics, Inc. and OncXerna Therapeutics, Inc.

 


 

Planning Committee and Reviewer Disclosures


 

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.


 

Accreditation, Support, and Credit


    
 
   
     
       
       
     
   
 
JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 

Support


 

This activity is supported by an educational grant from Lilly.


 

Physicians


 

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


 

The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).


 

MOC Statement


 
   
     
       
       
     
   
 
MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points  and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

 

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).


 

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.


 

Nurses


 

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.


 

Pharmacists


 

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.

    Universal Activity Number: JA4008289-0000-24-004-H01-P

    Type of Activity: Application


 

Physician Assistants


 
   
     
       
       
     
   
 
AAPA PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 2/9/2025. PAs should only claim credit commensurate with the extent of their participation.

 

Interprofessional Continuing Education (IPCE) Statement


 
   
     
       
       
     
   
 
IPCE This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

 

Method of Participation


 

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

   

    A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

   

    If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD), and a score of 75% or higher is needed to obtain MOC/CC credit.

   

    For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

   

    For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.


 

Disclosure of Unlabeled Use


 

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


 

About This CME/MOC/NCPD/CPE/AAPA/IPCE Activity


 

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.


 

Copyright © 2000-2024, PeerView



 
 

Custom Care Compass: Mastering Multifactorial Clinical Decision-Making in High-Risk HR+, HER2- MBC


 

Media: Enduring Material

    Activity Release Date: January 10, 2024

    Activity Expiration Date: February 9, 2025

    Time to Complete Activity: 60 minutes


 

Activity Description


 

The standard of care for patients with HR+, HER2- locally advanced unresectable or metastatic breast cancer (MBC) in the first-line setting involves endocrine therapy in combination with a CDK4/6 inhibitor. However, questions persist regarding the optimal use of each CDK4/6 inhibitor in first- and later-line settings. Ongoing research, fortunately, is providing new insights into the use of CDK4/6 inhibitors. Additionally, a number of investigational therapies with the potential to change clinical practice are showing great promise, with some recently approved in the metastatic setting. These investigational therapies include novel oral SERDs, ATK inhibition, and antibody–drug conjugates, such as those targeting HER2 and TROP2. With these therapies proving their clinical potential, it is essential to learn how to best integrate them into the current treatment arsenal. Furthermore, various patient- and disease-related factors such as age, HR status, metastatic sites, visceral involvement, endocrine resistance, tumor grade, disease-free interval, and molecular profile must be considered for optimal individualized therapy as well. In this PeerView Live virtual workshop, presented through a case-based framework, leading experts review the latest clinical evidence and provide practical strategies on navigating the complexities of clinical decision-making and selection and sequencing of therapies. The panel also addresses the nuances of treatment delivery and best practices for mitigating and managing adverse events associated with CDK4/6 inhibitors to help patients with HR+, HER2- MBC achieve the best possible outcomes.


 

Target Audience


 

This activity has been designed to meet the educational needs of oncologists, advanced practice clinicians, nurses, pharmacists, and other healthcare professionals involved in the care of patients with HR+, HER2- MBC.


 

Educational Objectives


 

Upon completion of this activity, participants should be better able to:


 

  •    
  • Evaluate the latest efficacy and safety data supporting the use of CDK4/6 inhibitors, as well as new and emerging treatment options for patients with HR+, HER2- MBC, considering their evolving roles in clinical practice

  •    
  • Develop individualized treatment plans that integrate CDK4/6 inhibitor therapy for patients with HR+, HER2- MBC, based on the latest evidence, guidelines, and assessment of drug-, tumor/disease-, and patient-related factors

  •    
  • Implement team-based strategies to achieve optimal treatment adherence and persistence, as well as prevent and mitigate adverse events associated with different CDK4/6 inhibitors in the management of HR+, HER2- MBC

  •  

 

Disclosure Policy


 

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.


 

Faculty/Planner Disclosures


 

Chair/Planner

    Joyce O’Shaughnessy, MD

    Celebrating Women Chair in Breast Cancer Research

    Baylor University Medical Center

    Director, Breast Cancer Research Program

    Texas Oncology

    US Oncology

    Dallas, Texas


 

Joyce O’Shaughnessy, MD, has a financial interest/relationship or affiliation in the form of:

    Consultant and/or Advisor for AbbVie Inc.; Agendia; Amgen Inc.; Aptitude Health; AstraZeneca; Bayer HealthCare Pharmaceuticals, Inc.; Bristol Myers Squibb; Celgene Corporation; Daiichi Sankyo, Inc.; Duality Biologics; Eisai Inc.; F. Hoffmann-La Roche Ltd.; G1 Therapeutics, Inc.; Genentech, Inc.; Gilead Sciences, Inc.; GRAIL, Inc.; Halozyme, Inc.; Heron Therapeutics, Inc.; Immunomedics, Inc.; Ipsen Biopharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Myriad Genetics, Inc.; Nektar; Novartis Pharmaceuticals Corporation; Ontada LLC; Pfizer; Pharmacyclics LLC; Pierre Fabre group; prIME Oncology; Puma Biotechnology, Inc.; Samsung Bioepis; Sanofi; Scorpion Therapeutics, Inc.; Seagen Inc.; Stemline Therapeutics, Inc./The Menarini Group; Syndax Pharmaceuticals Inc.; Synthon; Taiho Oncology, Inc.; and Takeda Pharmaceutical Company Limited.

 


 

Faculty/Planner

    Sara M. Tolaney, MD, MPH

    Chief, Division of Breast Oncology

    Associate Director

    Susan F. Smith Center for Women’s Cancers

    Senior Physician

    Dana-Farber Cancer Institute

    Associate Professor of Medicine

    Harvard Medical School

    Boston, Massachusetts


 

Sara M. Tolaney, MD, MPH, has a financial interest/relationship or affiliation in the form of:

    Consultant and/or Advisor for 4D pharma plc; Aadi Bioscience, Inc.; ARC Therapeutics; Artios Pharma; AstraZeneca; Bayer HealthCare Pharmaceuticals, Inc.; BeyondSpring Pharmaceuticals Inc.; Blueprint Medicines; Bristol Myers Squibb; CytomX Therapeutics, Inc.; Daiichi Sankyo Inc.; eFFECTOR Therapeutics; Eisai Inc.; Exelixis, Inc.; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Gilead Sciences, Inc.; Incyte; Jazz Pharmaceuticals; Lilly; Merck & Co., Inc.; Myovant Sciences Ltd.; Natera; Novartis Pharmaceuticals Corporation; Pfizer; Reveal Genomics; Sanofi; Seattle Genetics, Inc.; Stemline Therapeutics, Inc./The Menarini Group; Systimmune; Tango Therapeutics; Umoja Biopharma; Zentalis; Zetagen; and Zymeworks Inc.

    Grant/Research Support from AstraZeneca; Bristol Myers Squibb; Cyclacel Pharmaceuticals, Inc.; Eisai Inc.; Exelixis, Inc.; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Gilead Sciences, Inc.; Lilly; Merck & Co., Inc.; NanoString Technologies Inc.; Nektar; Novartis Pharmaceuticals Corporation; Pfizer; Sanofi; and Seattle Genetics, Inc.

    Other Financial or Material Support from Steering committee for CytomX Therapeutics, Inc. and OncXerna Therapeutics, Inc.

 


 

Planning Committee and Reviewer Disclosures


 

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.


 

Accreditation, Support, and Credit


    
 
   
     
       
       
     
   
 
JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 

Support


 

This activity is supported by an educational grant from Lilly.


 

Physicians


 

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


 

The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).


 

MOC Statement


 
   
     
       
       
     
   
 
MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points  and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

 

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).


 

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.


 

Nurses


 

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.


 

Pharmacists


 

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.

    Universal Activity Number: JA4008289-0000-24-004-H01-P

    Type of Activity: Application


 

Physician Assistants


 
   
     
       
       
     
   
 
AAPA PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 2/9/2025. PAs should only claim credit commensurate with the extent of their participation.

 

Interprofessional Continuing Education (IPCE) Statement


 
   
     
       
       
     
   
 
IPCE This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

 

Method of Participation


 

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

   

    A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

   

    If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD), and a score of 75% or higher is needed to obtain MOC/CC credit.

   

    For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

   

    For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.


 

Disclosure of Unlabeled Use


 

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


 

About This CME/MOC/NCPD/CPE/AAPA/IPCE Activity


 

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.


 

Copyright © 2000-2024, PeerView


January 10, 2024
Credits: 1.0 CME / NCPD / CPE / AAPA / IPCE
PVI, PeerView Institute for Medical Education
Getting Personal: Reassessing HIV Management to Better Individualize Treatment Across the Ages

Getting Personal: Reassessing HIV Management to Better Individualize Treatment Across the Ages

Start

Getting Personal: Reassessing HIV Management to Better Individualize Treatment Across the Ages

Media: Enduring Material
Activity Release Date: December 13, 2023
Activity Expiration Date: December 12, 2024
Time to Complete Activity: 60 minutes

Activity Description

In this activity, an expert discusses identifying barriers that threaten ending the HIV epidemic, current and emerging treatment options in HIV management, and ways to personalize treatment for patients living with HIV to improve outcomes and adherence.

Target Audience

This activity has been designed to meet the educational needs of HIV care providers, primary care providers and general practitioners, advanced practice providers, nurses, pharmacists, and other professionals involved in the care of patients living with HIV.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Identify patient barriers that may contribute to poor persistence with HIV treatment
  • Counsel patients living with HIV about the benefits and flexibility of current and emerging options in treatment and the importance of remaining adherent to therapy
  • Personalize treatment for patients living with HIV based on therapeutic mechanism of action, route of administration, efficacy, safety, and resistance profiles, considering each patient’s individual needs across the age span (adolescence, child-bearing years, aged >65 years)
  • Implement team-based HIV management strategies that ensure health equity, access and adherence to treatment, and ongoing monitoring for resistance

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Professor Chloe Orkin
Professor of Infection and Inequities
Queen Mary University of London
Barts Health NHS Trust
London, England, United Kingdom

Professor Chloe Orkin has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Gilead Sciences, Inc.; GSK; Merck Sharp & Dohme; and ViiV Healthcare group of companies.
Grant/Research Support from Gilead Sciences, Inc. and ViiV Healthcare group of companies.
Speaker for Gilead Sciences, Inc.; GSK; Merck Sharp & Dohme; and ViiV Healthcare group of companies.

Patient Advocate/Planner
Shawnte' Spriggs

Shawnte' Spriggs has no financial interests/relationships or affiliations in relation to this activity.

Patient Advocate/Planner
Donald Young

Donald Young has no financial interests/relationships or affiliations in relation to this activity.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This program has been supported by an independent educational grant from Gilead Sciences, Inc.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 0.75 contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-9999-23-069-H02-P
Type of Activity: Knowledge

Physician Assistants

AAPA PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 12/12/2024. PAs should only claim credit commensurate with the extent of their participation.

Interprofessional Continuing Education (IPCE) Statement

IPCE This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/NCPD/CPE/AAPA/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2023, PeerView

Getting Personal: Reassessing HIV Management to Better Individualize Treatment Across the Ages

Media: Enduring Material
Activity Release Date: December 13, 2023
Activity Expiration Date: December 12, 2024
Time to Complete Activity: 60 minutes

Activity Description

In this activity, an expert discusses identifying barriers that threaten ending the HIV epidemic, current and emerging treatment options in HIV management, and ways to personalize treatment for patients living with HIV to improve outcomes and adherence.

Target Audience

This activity has been designed to meet the educational needs of HIV care providers, primary care providers and general practitioners, advanced practice providers, nurses, pharmacists, and other professionals involved in the care of patients living with HIV.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Identify patient barriers that may contribute to poor persistence with HIV treatment
  • Counsel patients living with HIV about the benefits and flexibility of current and emerging options in treatment and the importance of remaining adherent to therapy
  • Personalize treatment for patients living with HIV based on therapeutic mechanism of action, route of administration, efficacy, safety, and resistance profiles, considering each patient’s individual needs across the age span (adolescence, child-bearing years, aged >65 years)
  • Implement team-based HIV management strategies that ensure health equity, access and adherence to treatment, and ongoing monitoring for resistance

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Professor Chloe Orkin
Professor of Infection and Inequities
Queen Mary University of London
Barts Health NHS Trust
London, England, United Kingdom

Professor Chloe Orkin has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Gilead Sciences, Inc.; GSK; Merck Sharp & Dohme; and ViiV Healthcare group of companies.
Grant/Research Support from Gilead Sciences, Inc. and ViiV Healthcare group of companies.
Speaker for Gilead Sciences, Inc.; GSK; Merck Sharp & Dohme; and ViiV Healthcare group of companies.

Patient Advocate/Planner
Shawnte' Spriggs

Shawnte' Spriggs has no financial interests/relationships or affiliations in relation to this activity.

Patient Advocate/Planner
Donald Young

Donald Young has no financial interests/relationships or affiliations in relation to this activity.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This program has been supported by an independent educational grant from Gilead Sciences, Inc.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 0.75 contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-9999-23-069-H02-P
Type of Activity: Knowledge

Physician Assistants

AAPA PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 12/12/2024. PAs should only claim credit commensurate with the extent of their participation.

Interprofessional Continuing Education (IPCE) Statement

IPCE This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/NCPD/CPE/AAPA/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2023, PeerView

December 13, 2023
Credits: 0.5 CME / MOC / NCPD / CPE / AAPA / IPCE
PVI, PeerView Institute for Medical Education
Equitably Empowering Our Upper GI Cancer Patients Using Plain Language Tools to Improve Outcomes With Immunotherapeutic Regimens Through Informed Shared Decision-Making

Equitably Empowering Our Upper GI Cancer Patients Using Plain Language Tools to Improve Outcomes With Immunotherapeutic Regimens Through Informed Shared Decision-Making

Start

Equitably Empowering Our Upper GI Cancer Patients Using Plain Language Tools to Improve Outcomes With Immunotherapeutic Regimens Through Informed Shared Decision-Making

Media: Enduring Material
Activity Release Date: December 13, 2023
Activity Expiration Date: December 12, 2024
Time to Complete Activity: 30 minutes

Activity Description

The establishment of immunotherapy-based regimens in the modern treatment paradigm for upper GI Cancers, including gastric and gastroesophageal junction (GEJ) cancers, is placing increased importance on close collaboration between the clinical care team and patients and caregivers, to promote engagement in a process of informed shared decision-making (SDM) when selecting treatment plans that are tailored to patient-specific needs, values, and preferences.

In this PeerView activity, an oncologist, who is an expert in GI cancers, will present practice-changing evidence for integrating immunotherapy approaches into treatment plans; give insights on the rationale and benefits of engaging patients in informed shared decision-making when choosing treatment options; and explore the available tools when making informed shared decisions about immuno-oncology strategies as part of a team-based, equitable management approach, using the CheckMate -649 plain language summary as an example that can be downloaded for your use. Don’t miss this unique opportunity to enhance your skills in patient engagement to promote SDM in your practice!

Target Audience

This activity has been designed to meet the educational needs of medical oncologists, nurse practitioners, physician assistants, nurses, pharmacists, and other care team professionals involved in the treatment of patients with upper GI cancers.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Describe current evidence-based, guideline-recommended protocols for integrating immuno-oncology approaches into treatment plans for patients with upper GI cancers across disease settings
  • Explain the benefits of engaging patients with upper GI cancers in informed shared decision-making by the healthcare team when choosing a treatment option including the effects on patient engagement in the selected treatment plan
  • Utilize available tools including plain language summaries when making informed shared decisions about including immuno-oncology strategies as part of a team-based, equitable management approach to upper GI malignancies

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Yelena Y. Janjigian*, MD
Professor and Chief of Gastrointestinal Oncology Service
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

*This activity was developed with Yelena Y. Janjigian, MD, and is not affiliated in any capacity with Memorial Sloan Kettering Cancer Center.

Yelena Y. Janjigian*, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie, Inc.; AmerisourceBergen; Arcus Biosciences; AskGene Pharma, Inc.; Astellas Pharma Inc.; AstraZeneca; Basilea Pharmaceutica Ltd.; Bayer Corporation; Bristol Myers Squibb; Daiichi Sankyo Inc.; GlaxoSmithKline; Guardant Health; Imugene Limited; Inspirna, Inc.; Lilly; Merck & Co., Inc.; Merck Serono; Mersana Therapeutics Inc.; Pfizer; Rgenix Inc.; Seagen Inc.; Silverback Therapeutics (ARS Pharmaceuticals) and Zymeworks Inc.
Grant/Research Support from Arcus Biosciences; AstraZeneca; Bayer HealthCare Pharmaceuticals, Inc.; Bristol Myers Squibb; Cycle for Survival; Fred's Team; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Inspirna, Inc.; Lilly; Merck & Co., Inc.; National Cancer Institute; Transcenta Holding; and U.S. Department of Defense.
Stock Shareholder in Inspirna, Inc.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported through an educational grant from Bristol Myers Squibb.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 0.5 contact hour(s) and no contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 0.5 contact hours (0.05 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-23-073-H01-P
Type of Activity: Knowledge

Physician Assistants

AAPA PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. Approval is valid until 12/12/2024. PAs should only claim credit commensurate with the extent of their participation.

Interprofessional Continuing Education (IPCE) Statement

IPCE This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD/CPE/AAPA/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2023, PeerView

Equitably Empowering Our Upper GI Cancer Patients Using Plain Language Tools to Improve Outcomes With Immunotherapeutic Regimens Through Informed Shared Decision-Making

Media: Enduring Material
Activity Release Date: December 13, 2023
Activity Expiration Date: December 12, 2024
Time to Complete Activity: 30 minutes

Activity Description

The establishment of immunotherapy-based regimens in the modern treatment paradigm for upper GI Cancers, including gastric and gastroesophageal junction (GEJ) cancers, is placing increased importance on close collaboration between the clinical care team and patients and caregivers, to promote engagement in a process of informed shared decision-making (SDM) when selecting treatment plans that are tailored to patient-specific needs, values, and preferences.

In this PeerView activity, an oncologist, who is an expert in GI cancers, will present practice-changing evidence for integrating immunotherapy approaches into treatment plans; give insights on the rationale and benefits of engaging patients in informed shared decision-making when choosing treatment options; and explore the available tools when making informed shared decisions about immuno-oncology strategies as part of a team-based, equitable management approach, using the CheckMate -649 plain language summary as an example that can be downloaded for your use. Don’t miss this unique opportunity to enhance your skills in patient engagement to promote SDM in your practice!

Target Audience

This activity has been designed to meet the educational needs of medical oncologists, nurse practitioners, physician assistants, nurses, pharmacists, and other care team professionals involved in the treatment of patients with upper GI cancers.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Describe current evidence-based, guideline-recommended protocols for integrating immuno-oncology approaches into treatment plans for patients with upper GI cancers across disease settings
  • Explain the benefits of engaging patients with upper GI cancers in informed shared decision-making by the healthcare team when choosing a treatment option including the effects on patient engagement in the selected treatment plan
  • Utilize available tools including plain language summaries when making informed shared decisions about including immuno-oncology strategies as part of a team-based, equitable management approach to upper GI malignancies

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Yelena Y. Janjigian*, MD
Professor and Chief of Gastrointestinal Oncology Service
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

*This activity was developed with Yelena Y. Janjigian, MD, and is not affiliated in any capacity with Memorial Sloan Kettering Cancer Center.

Yelena Y. Janjigian*, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie, Inc.; AmerisourceBergen; Arcus Biosciences; AskGene Pharma, Inc.; Astellas Pharma Inc.; AstraZeneca; Basilea Pharmaceutica Ltd.; Bayer Corporation; Bristol Myers Squibb; Daiichi Sankyo Inc.; GlaxoSmithKline; Guardant Health; Imugene Limited; Inspirna, Inc.; Lilly; Merck & Co., Inc.; Merck Serono; Mersana Therapeutics Inc.; Pfizer; Rgenix Inc.; Seagen Inc.; Silverback Therapeutics (ARS Pharmaceuticals) and Zymeworks Inc.
Grant/Research Support from Arcus Biosciences; AstraZeneca; Bayer HealthCare Pharmaceuticals, Inc.; Bristol Myers Squibb; Cycle for Survival; Fred's Team; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Inspirna, Inc.; Lilly; Merck & Co., Inc.; National Cancer Institute; Transcenta Holding; and U.S. Department of Defense.
Stock Shareholder in Inspirna, Inc.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported through an educational grant from Bristol Myers Squibb.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 0.5 contact hour(s) and no contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 0.5 contact hours (0.05 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-23-073-H01-P
Type of Activity: Knowledge

Physician Assistants

AAPA PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. Approval is valid until 12/12/2024. PAs should only claim credit commensurate with the extent of their participation.

Interprofessional Continuing Education (IPCE) Statement

IPCE This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD/CPE/AAPA/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2023, PeerView

December 13, 2023
Credits: 0.75 CME / NCPD / CPE / AAPA / IPCE
PVI, PeerView Institute for Medical Education
Elevating Outcomes for HER2-Expressing GI Cancers: The Evolving Role of Molecularly Targeted Agents in BTC and GEA Care

Elevating Outcomes for HER2-Expressing GI Cancers: The Evolving Role of Molecularly Targeted Agents in BTC and GEA Care

Start

Elevating Outcomes for HER2-Expressing GI Cancers: The Evolving Role of Molecularly Targeted Agents in BTC and GEA Care

Expert commentary is based on data presented at the European Society for Medical Oncology (ESMO) Congress 2023.
PeerView is an independent publisher of conference news and medical education programs.

Media: Enduring Material
Activity Release Date: November 28, 2023
Activity Expiration Date: November 27, 2024
Time to Complete Activity: 45 minutes

Activity Description

Emerging evidence supporting modern targeted strategies for the management of biliary tract cancers (BTC) and gastroesophageal adenocarcinoma (GEA) has led to the development of several agents to personalize therapy for patients with HER2-expressing malignancies.

In collaboration with the Cholangiocarcinoma Foundation, this activity will provide the latest updates on evolving, evidence-based practice standards for HER2-targeting agents, including emerging data arising from the 2023 ESMO Congress. Through a conversational exchange of ideas combined with compelling, case-based instruction, experts will engage in discussions of real-world patient scenarios to illustrate best practices for the management of HER2-expressing BTC and GEA, including overcoming barriers associated with baseline molecular testing for personalized therapy selection.

Target Audience

This activity has been designed to meet the educational needs of medical oncologists, gastrointestinal oncologists, hepatobiliary surgeons, hepatologists, gastroenterologists, physician assistants, nurse practitioners, pharmacists, and other healthcare professionals involved in the care of patients with GI cancers.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Summarize current evidence supporting targeted agents for the management of HER2-positive GI cancers, including safety/efficacy profiles, dosing considerations, and their role in current treatment protocols
  • Develop individualized treatment plans based on molecular findings, current and emerging clinical evidence, and guideline recommendations when managing patients with HER2-expressing BTC and GEA
  • Integrate team-based strategies to prevent and manage well-documented adverse events associated with HER2-targeting therapies when managing patients with BTC and GEA

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Co-Chair/Planner
Josep Tabernero, MD, PhD
Head, Medical Oncology Department, Vall d’Hebron University Hospital (HUVH)
Director, Vall d’Hebron Institute of Oncology (VHIO)
Barcelona, Spain

Josep Tabernero, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Boehringer Ingelheim International GmbH; Cardiff Oncology, Inc.; CARsgen Therapeutics; Chugai Pharmaceutical Co., Ltd.; Daiichi Sankyo, Inc.; F. Hoffmann-La Roche Ltd; Genentech Inc; hC Bioscience, Inc.; Ikena Oncology; Inspirna, Inc.; Lilly; Menarini; Merck Serono; Merck Sharp & Dohme; Merus; Mirati Therapeutics Inc.; NeoPhore; Novartis AG; Ona Therapeutics; Orion Biotechnology; Peptomyc; Pfizer; Pierre Fabre; Samsung Bioepis; Sanofi; Scandion Oncology A/S; Scorpion Therapeutics; Seagen; Servier; SOTIO Biotech AG; Taiho; Takeda Oncology, ; and TOLREMO Therapeutics AG.
Stock Shareholder in Oniria Therapeutics, Alentis Therapeutics, Pangaea Oncology and 1TRIALSP.

Co-Chair/Planner
Shubham Pant, MD
Professor
Department of Gastrointestinal Medical Oncology
Department of Investigational Cancer Therapeutics
The University of Texas MD Anderson Cancer Center
Houston, Texas

Shubham Pant, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AskGene Pharma Inc.; Boehringer Ingelheim International GmbH; Ipsen Pharma; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; and Zymeworks Inc.
Grant/Research Support from 4D Pharma; Amal Therapeutics; Arcus Biosciences; Astellas Pharma Inc.; BioNTech; Boehringer Ingelheim International GmbH; Bristol Myers Squibb; Elicio Therapeutics; Immuneering Corporation; ImmunoMET; Ipsen Pharma; Janssen Pharmaceuticals, Inc.; Lilly; Mirati Therapeutics, Inc.; NGM Biopharmaceuticals; Novartis Pharmaceuticals Corporation; Pfizer; Purple Biotech; Rgenix; Xencor; and Zymeworks Inc. All goes to Institution.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

JAP In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Cholangiocarcinoma Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This program is supported by an independent medical education grant from Jazz Pharmaceuticals.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 0.75 contact hour(s) and 0.75 contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 0.75 contact hours (0.075 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-9999-23-072-H01-P
Type of Activity: Knowledge

Physician Assistants

AAPA PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credits. Approval is valid until 11/27/2024. PAs should only claim credit commensurate with the extent of their participation.

Interprofessional Continuing Education (IPCE) Statement

IPCE This activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education (IPCE) credits for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/NCPD/CPE/AAPA/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2023, PeerView

Elevating Outcomes for HER2-Expressing GI Cancers: The Evolving Role of Molecularly Targeted Agents in BTC and GEA Care

Expert commentary is based on data presented at the European Society for Medical Oncology (ESMO) Congress 2023.
PeerView is an independent publisher of conference news and medical education programs.

Media: Enduring Material
Activity Release Date: November 28, 2023
Activity Expiration Date: November 27, 2024
Time to Complete Activity: 45 minutes

Activity Description

Emerging evidence supporting modern targeted strategies for the management of biliary tract cancers (BTC) and gastroesophageal adenocarcinoma (GEA) has led to the development of several agents to personalize therapy for patients with HER2-expressing malignancies.

In collaboration with the Cholangiocarcinoma Foundation, this activity will provide the latest updates on evolving, evidence-based practice standards for HER2-targeting agents, including emerging data arising from the 2023 ESMO Congress. Through a conversational exchange of ideas combined with compelling, case-based instruction, experts will engage in discussions of real-world patient scenarios to illustrate best practices for the management of HER2-expressing BTC and GEA, including overcoming barriers associated with baseline molecular testing for personalized therapy selection.

Target Audience

This activity has been designed to meet the educational needs of medical oncologists, gastrointestinal oncologists, hepatobiliary surgeons, hepatologists, gastroenterologists, physician assistants, nurse practitioners, pharmacists, and other healthcare professionals involved in the care of patients with GI cancers.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Summarize current evidence supporting targeted agents for the management of HER2-positive GI cancers, including safety/efficacy profiles, dosing considerations, and their role in current treatment protocols
  • Develop individualized treatment plans based on molecular findings, current and emerging clinical evidence, and guideline recommendations when managing patients with HER2-expressing BTC and GEA
  • Integrate team-based strategies to prevent and manage well-documented adverse events associated with HER2-targeting therapies when managing patients with BTC and GEA

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Co-Chair/Planner
Josep Tabernero, MD, PhD
Head, Medical Oncology Department, Vall d’Hebron University Hospital (HUVH)
Director, Vall d’Hebron Institute of Oncology (VHIO)
Barcelona, Spain

Josep Tabernero, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Boehringer Ingelheim International GmbH; Cardiff Oncology, Inc.; CARsgen Therapeutics; Chugai Pharmaceutical Co., Ltd.; Daiichi Sankyo, Inc.; F. Hoffmann-La Roche Ltd; Genentech Inc; hC Bioscience, Inc.; Ikena Oncology; Inspirna, Inc.; Lilly; Menarini; Merck Serono; Merck Sharp & Dohme; Merus; Mirati Therapeutics Inc.; NeoPhore; Novartis AG; Ona Therapeutics; Orion Biotechnology; Peptomyc; Pfizer; Pierre Fabre; Samsung Bioepis; Sanofi; Scandion Oncology A/S; Scorpion Therapeutics; Seagen; Servier; SOTIO Biotech AG; Taiho; Takeda Oncology, ; and TOLREMO Therapeutics AG.
Stock Shareholder in Oniria Therapeutics, Alentis Therapeutics, Pangaea Oncology and 1TRIALSP.

Co-Chair/Planner
Shubham Pant, MD
Professor
Department of Gastrointestinal Medical Oncology
Department of Investigational Cancer Therapeutics
The University of Texas MD Anderson Cancer Center
Houston, Texas

Shubham Pant, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AskGene Pharma Inc.; Boehringer Ingelheim International GmbH; Ipsen Pharma; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; and Zymeworks Inc.
Grant/Research Support from 4D Pharma; Amal Therapeutics; Arcus Biosciences; Astellas Pharma Inc.; BioNTech; Boehringer Ingelheim International GmbH; Bristol Myers Squibb; Elicio Therapeutics; Immuneering Corporation; ImmunoMET; Ipsen Pharma; Janssen Pharmaceuticals, Inc.; Lilly; Mirati Therapeutics, Inc.; NGM Biopharmaceuticals; Novartis Pharmaceuticals Corporation; Pfizer; Purple Biotech; Rgenix; Xencor; and Zymeworks Inc. All goes to Institution.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

JAP In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Cholangiocarcinoma Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This program is supported by an independent medical education grant from Jazz Pharmaceuticals.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 0.75 contact hour(s) and 0.75 contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 0.75 contact hours (0.075 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-9999-23-072-H01-P
Type of Activity: Knowledge

Physician Assistants

AAPA PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credits. Approval is valid until 11/27/2024. PAs should only claim credit commensurate with the extent of their participation.

Interprofessional Continuing Education (IPCE) Statement

IPCE This activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education (IPCE) credits for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/NCPD/CPE/AAPA/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2023, PeerView

November 27, 2023
Credits: 0.5 CME / MOC / CPE / AAPA / IPCE
PVI, PeerView Institute for Medical Education
Making Choices, Improving Outcomes in Pediatric ALL: The Role of Modern Asparaginase Compounds

Making Choices, Improving Outcomes in Pediatric ALL: The Role of Modern Asparaginase Compounds

Start

Making Choices, Improving Outcomes in Pediatric ALL: The Role of Modern Asparaginase Compounds

Media: Enduring Material
Activity Release Date: November 10, 2023
Activity Expiration Date: November 9, 2024
Time to Complete Activity: 30 minutes

Activity Description

The use of asparaginase as a component of multiagent chemotherapy has been clearly linked to optimal outcomes in pediatric acute lymphoblastic leukemia (ALL) populations. The approval of newer asparaginase formulations and dosing schedules has added to the growing collection of tools that clinicians can use to overcome challenges associated with consistent therapeutic exposure to asparaginase in ALL—but are you up to the task? This customizable, question-based activity covers the use of asparaginase compounds in pediatric ALL, the pitfalls of asparaginase discontinuation, and challenges such as hypersensitivity/silent inactivation. Test yourself and see if your choices will support the effective use of asparaginase as part of modern ALL therapy!

Target Audience

This activity has been designed to meet the educational needs of hematologists, hematologist-oncologists, advanced practice clinicians, pharmacists, other healthcare professionals, and other clinicians involved in the care of patients with acute lymphoblastic leukemia.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Describe the latest safety and efficacy evidence and unmet medical needs related to the optimal use of asparaginase in pediatric ALL, including the role of novel Erwinia asparaginase compounds
  • Develop therapeutic plans for adequate asparaginase exposure that incorporate appropriate dosing, avoidance of truncation/discontinuation, and monitoring for hypersensitivity/toxicity or silent inactivation
  • Implement team-based strategies to prevent therapy discontinuation or compromised patient outcomes in pediatric ALL, such as switching to alternative asparaginase formulations

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Luke Maese, DO
Associate Professor, Pediatrics
University of Utah - Huntsman Cancer Institute
Pediatric Hematology/Oncology
Director, Clinical Trial Research Enterprise
Director, Leukemia/Lymphoma Program
Primary Children's Hospital
Salt Lake City, Utah

Luke Maese, DO, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Jazz Pharmaceuticals.
Speaker for Jazz Pharmaceuticals.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This program is supported by an independent medical education grant from Jazz Pharmaceuticals.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 0.5 contact hours (0.05 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-23-070-H01-P
Type of Activity: Knowledge

Physician Assistants

AAPA PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. Approval is valid until 11/9/2024. PAs should only claim credit commensurate with the extent of their participation.

Interprofessional Continuing Education (IPCE) Statement

IPCE This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is needed to obtain MOC/CC credit.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/CPE/AAPA/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2023, PeerView

Making Choices, Improving Outcomes in Pediatric ALL: The Role of Modern Asparaginase Compounds

Media: Enduring Material
Activity Release Date: November 10, 2023
Activity Expiration Date: November 9, 2024
Time to Complete Activity: 30 minutes

Activity Description

The use of asparaginase as a component of multiagent chemotherapy has been clearly linked to optimal outcomes in pediatric acute lymphoblastic leukemia (ALL) populations. The approval of newer asparaginase formulations and dosing schedules has added to the growing collection of tools that clinicians can use to overcome challenges associated with consistent therapeutic exposure to asparaginase in ALL—but are you up to the task? This customizable, question-based activity covers the use of asparaginase compounds in pediatric ALL, the pitfalls of asparaginase discontinuation, and challenges such as hypersensitivity/silent inactivation. Test yourself and see if your choices will support the effective use of asparaginase as part of modern ALL therapy!

Target Audience

This activity has been designed to meet the educational needs of hematologists, hematologist-oncologists, advanced practice clinicians, pharmacists, other healthcare professionals, and other clinicians involved in the care of patients with acute lymphoblastic leukemia.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Describe the latest safety and efficacy evidence and unmet medical needs related to the optimal use of asparaginase in pediatric ALL, including the role of novel Erwinia asparaginase compounds
  • Develop therapeutic plans for adequate asparaginase exposure that incorporate appropriate dosing, avoidance of truncation/discontinuation, and monitoring for hypersensitivity/toxicity or silent inactivation
  • Implement team-based strategies to prevent therapy discontinuation or compromised patient outcomes in pediatric ALL, such as switching to alternative asparaginase formulations

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Luke Maese, DO
Associate Professor, Pediatrics
University of Utah - Huntsman Cancer Institute
Pediatric Hematology/Oncology
Director, Clinical Trial Research Enterprise
Director, Leukemia/Lymphoma Program
Primary Children's Hospital
Salt Lake City, Utah

Luke Maese, DO, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Jazz Pharmaceuticals.
Speaker for Jazz Pharmaceuticals.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This program is supported by an independent medical education grant from Jazz Pharmaceuticals.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 0.5 contact hours (0.05 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-23-070-H01-P
Type of Activity: Knowledge

Physician Assistants

AAPA PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. Approval is valid until 11/9/2024. PAs should only claim credit commensurate with the extent of their participation.

Interprofessional Continuing Education (IPCE) Statement

IPCE This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is needed to obtain MOC/CC credit.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/CPE/AAPA/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2023, PeerView

November 09, 2023
Credits: 1.5 CME / NCPD / CPE / AAPA
PVI, PeerView Institute for Medical Education
Antibody–Drug Conjugates, the Ultimate Weapons Against Solid Tumors: Latest Progress, Future Possibilities, and Implications for Patient Care

Antibody–Drug Conjugates, the Ultimate Weapons Against Solid Tumors: Latest Progress, Future Possibilities, and Implications for Patient Care

Start

Antibody–Drug Conjugates, the Ultimate Weapons Against Solid Tumors: Latest Progress, Future Possibilities, and Implications for Patient Care

Media: Enduring Material
Activity Release Date: November 10, 2023
Activity Expiration Date: December 9, 2024
Time to Complete Activity: 90 minutes

Activity Description

Antibody–drug conjugates (ADCs), including those targeting HER2, HER3, and TROP2, are an exciting new class of therapies that selectively deliver cytotoxic payloads to cancer cells. Recent regulatory approvals have cemented the role of ADCs in the treatment of various solid tumors, motivating further innovation to expand their use in other tumor types and disease settings. The new ADC era brings hope to patients with unmet needs, and keeping current with the latest advances, applying evidence to practice, mitigating adverse events, and identifying patients eligible to received ADCs in practice and clinical trials are more important than ever.

This PeerView educational activity, based on a recent live symposium, offers expert guidance on how to interpret and apply the latest evidence on HER2-, HER3-, TROP2-targeting, and other ADCs in the treatment of different solid tumors. Strategies for decision-making and optimizing outcomes for patients with cancer who may benefit from ADCs are also discussed, and case-based clinical scenarios highlight the practical considerations related to using ADCs in real-world care settings.

Target Audience

This activity has been designed to meet the educational needs of advanced practitioners in oncology and other clinicians involved in the management of patients with solid tumors.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Describe the rationale for use, mechanisms of action, safety and efficacy profiles based on available clinical evidence, and evolving clinical roles of the different ADCs targeting HER2, HER3, and TROP2 in solid tumors
  • Identify patients with solid tumors who might benefit from HER2-, HER3-, and TROP2-targeting ADCs in clinical practice or through clinical trial enrollment
  • Integrate approved and emerging therapies such as HER2-, HER3-, and TROP2-targeting ADCs safely and effectively into treatment plans of eligible patients with solid tumors according to the latest evidence and guidelines
  • Implement best practices for identifying and managing treatment-related adverse events in patients with solid tumors receiving ADC therapies to promote optimal adherence, outcomes, and quality of life

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Beth Sandy, MSN, CRNP, FAPO
Thoracic Oncology Nurse Practitioner
Abramson Cancer Center
University of Pennsylvania
Philadelphia, Pennsylvania

Beth Sandy, MSN, CRNP, FAPO, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc. and Janssen Pharmaceuticals, Inc.
Speakers Bureau participant with Amgen Inc.; AstraZeneca; Jazz Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; and Takeda Pharmaceutical Company Limited.

Faculty/Planner
Jamie Carroll, APRN, CNP, MSN
Assistant Professor of Oncology
Nurse Practitioner
Mayo Clinic
Rochester, Minnesota

Jamie Carroll, APRN, CNP, MSN, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Lilly; Novartis Pharmaceuticals Corporation; Pfizer; Sermonix Pharmaceuticals; and Talzenna.
Speakers Bureau participant with Horizon CME and OncLive.

Faculty/Planner
Elizabeth Prechtel Dunphy, DNP, RN, ANP-BC, AOCN
Senior Advanced Practice Provider
Abramson Cancer Center at Penn Presbyterian Medical Center
Philadelphia, Pennsylvania

Elizabeth Prechtel Dunphy, DNP, RN, ANP-BC, AOCN, has a financial interest/relationship or affiliation in the form of:
Speakers Bureau participant with Incyte.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by independent educational grants from AstraZeneca and Daiichi Sankyo, Inc.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.5 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.

Nurse Practitioners

AANP This activity is approved for 1.5 contact hour(s) of continuing education (which includes 1.0 hours of pharmacology) by the American Association of Nurse Practitioners® (AANP). Activity ID# 23106433. This activity was planned in accordance with AANP Accreditation Standards and Policies.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 1.5 contact hours (0.15 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-23-049-H01-P
Type of Activity: Application

Physician Assistants

AAPA PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. Approval is valid until 12/9/2024. PAs should only claim credit commensurate with the extent of their participation.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/NCPD/CE/CPE/AAPA Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2023, PeerView

Antibody–Drug Conjugates, the Ultimate Weapons Against Solid Tumors: Latest Progress, Future Possibilities, and Implications for Patient Care

Media: Enduring Material
Activity Release Date: November 10, 2023
Activity Expiration Date: December 9, 2024
Time to Complete Activity: 90 minutes

Activity Description

Antibody–drug conjugates (ADCs), including those targeting HER2, HER3, and TROP2, are an exciting new class of therapies that selectively deliver cytotoxic payloads to cancer cells. Recent regulatory approvals have cemented the role of ADCs in the treatment of various solid tumors, motivating further innovation to expand their use in other tumor types and disease settings. The new ADC era brings hope to patients with unmet needs, and keeping current with the latest advances, applying evidence to practice, mitigating adverse events, and identifying patients eligible to received ADCs in practice and clinical trials are more important than ever.

This PeerView educational activity, based on a recent live symposium, offers expert guidance on how to interpret and apply the latest evidence on HER2-, HER3-, TROP2-targeting, and other ADCs in the treatment of different solid tumors. Strategies for decision-making and optimizing outcomes for patients with cancer who may benefit from ADCs are also discussed, and case-based clinical scenarios highlight the practical considerations related to using ADCs in real-world care settings.

Target Audience

This activity has been designed to meet the educational needs of advanced practitioners in oncology and other clinicians involved in the management of patients with solid tumors.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Describe the rationale for use, mechanisms of action, safety and efficacy profiles based on available clinical evidence, and evolving clinical roles of the different ADCs targeting HER2, HER3, and TROP2 in solid tumors
  • Identify patients with solid tumors who might benefit from HER2-, HER3-, and TROP2-targeting ADCs in clinical practice or through clinical trial enrollment
  • Integrate approved and emerging therapies such as HER2-, HER3-, and TROP2-targeting ADCs safely and effectively into treatment plans of eligible patients with solid tumors according to the latest evidence and guidelines
  • Implement best practices for identifying and managing treatment-related adverse events in patients with solid tumors receiving ADC therapies to promote optimal adherence, outcomes, and quality of life

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Beth Sandy, MSN, CRNP, FAPO
Thoracic Oncology Nurse Practitioner
Abramson Cancer Center
University of Pennsylvania
Philadelphia, Pennsylvania

Beth Sandy, MSN, CRNP, FAPO, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc. and Janssen Pharmaceuticals, Inc.
Speakers Bureau participant with Amgen Inc.; AstraZeneca; Jazz Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; and Takeda Pharmaceutical Company Limited.

Faculty/Planner
Jamie Carroll, APRN, CNP, MSN
Assistant Professor of Oncology
Nurse Practitioner
Mayo Clinic
Rochester, Minnesota

Jamie Carroll, APRN, CNP, MSN, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Lilly; Novartis Pharmaceuticals Corporation; Pfizer; Sermonix Pharmaceuticals; and Talzenna.
Speakers Bureau participant with Horizon CME and OncLive.

Faculty/Planner
Elizabeth Prechtel Dunphy, DNP, RN, ANP-BC, AOCN
Senior Advanced Practice Provider
Abramson Cancer Center at Penn Presbyterian Medical Center
Philadelphia, Pennsylvania

Elizabeth Prechtel Dunphy, DNP, RN, ANP-BC, AOCN, has a financial interest/relationship or affiliation in the form of:
Speakers Bureau participant with Incyte.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by independent educational grants from AstraZeneca and Daiichi Sankyo, Inc.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.5 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.

Nurse Practitioners

AANP This activity is approved for 1.5 contact hour(s) of continuing education (which includes 1.0 hours of pharmacology) by the American Association of Nurse Practitioners® (AANP). Activity ID# 23106433. This activity was planned in accordance with AANP Accreditation Standards and Policies.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 1.5 contact hours (0.15 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-23-049-H01-P
Type of Activity: Application

Physician Assistants

AAPA PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. Approval is valid until 12/9/2024. PAs should only claim credit commensurate with the extent of their participation.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/NCPD/CE/CPE/AAPA Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2023, PeerView

November 09, 2023
Credits: 1.0 CME / MOC / NCPD / CPE / AAPA / IPCE
PVI, PeerView Institute for Medical Education
Reviving the BTK Target in MCL: Recalibrating the Treatment Sequence With Non-Covalent BTK Inhibitors in R/R Disease

Reviving the BTK Target in MCL: Recalibrating the Treatment Sequence With Non-Covalent BTK Inhibitors in R/R Disease

Start

Reviving the BTK Target in MCL: Recalibrating the Treatment Sequence With Non-Covalent BTK Inhibitors in R/R Disease

Media: Enduring Material
Activity Release Date: October 27, 2023
Activity Expiration Date: November 26, 2024
Time to Complete Activity: 60 minutes

Activity Description

Covalent BTK inhibitors (cBTKi) have transformed the management of mantle cell lymphoma (MCL). However, their efficacy as second-line therapies is often hindered by intolerance and treatment resistance, leading to poor outcomes for many patients with relapsed/refractory (R/R) disease who discontinue cBTKi. Are you prepared to overcome this challenge by developing evidence-based sequential strategies for MCL treatment? Find out how to “revive” the BTK target by joining two MCL experts as they explore the integration of non-covalent BTKi (ncBTKi) in sequential R/R MCL care. Throughout, the experts use robust case discussion and 3D and 2D animations to provide guidance on developing ncBTKi-inclusive treatment plans that deliver safe and highly effective care while extending the clinical benefits of BTKi therapy.

Target Audience

This activity has been designed to meet the educational needs of hematologists, hematologist-oncologists, advanced practice clinicians, nurses, pharmacists, and other clinicians involved in the management of MCL.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Summarize the latest clinical evidence, mechanistic rationale, and current guidelines supporting the use of non-covalent BTKi agents in R/R MCL settings
  • Integrate non-covalent BTK inhibitors into modern sequential treatment plans for R/R MCL, including in settings of BTKi-intolerant, or -resistant disease
  • Develop collaborative protocols for addressing practical aspects of MCL care, including monitoring, patient education, and management of adverse events, when using BTKi strategies

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Co-Chair/Planner
Nirav Shah, MD, MS
Associate Professor of Medicine
Division of Hematology and Oncology
Froedtert Hospital and the Medical College of Wisconsin
Milwaukee, Wisconsin

Nirav Shah, MD, MS, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Bristol Myers Squibb-Juno Therapeutics Inc; Epizyme, Inc.; Incyte Corporation; Janssen Pharmaceuticals, Inc.; Kite, A Gilead Company; Loxo Oncology-Lilly; Miltenyi Biotec; Novartis Pharmaceuticals Corporation; Seattle Genetics, Inc.; TG Therapeutics, Inc.; and Umoja Biopharma.
Grant/Research Support from Loxo Oncology-Lilly and Miltenyi Biotec.

Co-Chair/Planner
Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD
Haematology Consultant
Oxford University Hospitals
NHS Foundation Trust
Oxford, United Kingdom

Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie; AstraZeneca; BeiGene; F. Hoffmann-La Roche AG; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Kite, A Gilead Company; Lilly; Loxo Oncology, Inc.; and Secura Bio, Inc.
Grant/Research Support from AstraZeneca and BeiGene.
Speaker for AbbVie; AstraZeneca; F. Hoffmann-La Roche AG; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Kite, A Gilead Company; Lilly; and Loxo Oncology, Inc.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by an educational grant from Lilly.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-23-064-H01-P
Type of Activity: Application

Physician Assistants

AAPA PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 11/26/2024. PAs should only claim credit commensurate with the extent of their participation.

Interprofessional Continuing Education (IPCE) Statement

IPCE This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD/CPE/AAPA/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2023, PeerView

Reviving the BTK Target in MCL: Recalibrating the Treatment Sequence With Non-Covalent BTK Inhibitors in R/R Disease

Media: Enduring Material
Activity Release Date: October 27, 2023
Activity Expiration Date: November 26, 2024
Time to Complete Activity: 60 minutes

Activity Description

Covalent BTK inhibitors (cBTKi) have transformed the management of mantle cell lymphoma (MCL). However, their efficacy as second-line therapies is often hindered by intolerance and treatment resistance, leading to poor outcomes for many patients with relapsed/refractory (R/R) disease who discontinue cBTKi. Are you prepared to overcome this challenge by developing evidence-based sequential strategies for MCL treatment? Find out how to “revive” the BTK target by joining two MCL experts as they explore the integration of non-covalent BTKi (ncBTKi) in sequential R/R MCL care. Throughout, the experts use robust case discussion and 3D and 2D animations to provide guidance on developing ncBTKi-inclusive treatment plans that deliver safe and highly effective care while extending the clinical benefits of BTKi therapy.

Target Audience

This activity has been designed to meet the educational needs of hematologists, hematologist-oncologists, advanced practice clinicians, nurses, pharmacists, and other clinicians involved in the management of MCL.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Summarize the latest clinical evidence, mechanistic rationale, and current guidelines supporting the use of non-covalent BTKi agents in R/R MCL settings
  • Integrate non-covalent BTK inhibitors into modern sequential treatment plans for R/R MCL, including in settings of BTKi-intolerant, or -resistant disease
  • Develop collaborative protocols for addressing practical aspects of MCL care, including monitoring, patient education, and management of adverse events, when using BTKi strategies

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Co-Chair/Planner
Nirav Shah, MD, MS
Associate Professor of Medicine
Division of Hematology and Oncology
Froedtert Hospital and the Medical College of Wisconsin
Milwaukee, Wisconsin

Nirav Shah, MD, MS, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Bristol Myers Squibb-Juno Therapeutics Inc; Epizyme, Inc.; Incyte Corporation; Janssen Pharmaceuticals, Inc.; Kite, A Gilead Company; Loxo Oncology-Lilly; Miltenyi Biotec; Novartis Pharmaceuticals Corporation; Seattle Genetics, Inc.; TG Therapeutics, Inc.; and Umoja Biopharma.
Grant/Research Support from Loxo Oncology-Lilly and Miltenyi Biotec.

Co-Chair/Planner
Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD
Haematology Consultant
Oxford University Hospitals
NHS Foundation Trust
Oxford, United Kingdom

Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie; AstraZeneca; BeiGene; F. Hoffmann-La Roche AG; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Kite, A Gilead Company; Lilly; Loxo Oncology, Inc.; and Secura Bio, Inc.
Grant/Research Support from AstraZeneca and BeiGene.
Speaker for AbbVie; AstraZeneca; F. Hoffmann-La Roche AG; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Kite, A Gilead Company; Lilly; and Loxo Oncology, Inc.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by an educational grant from Lilly.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-23-064-H01-P
Type of Activity: Application

Physician Assistants

AAPA PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 11/26/2024. PAs should only claim credit commensurate with the extent of their participation.

Interprofessional Continuing Education (IPCE) Statement

IPCE This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD/CPE/AAPA/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2023, PeerView

October 26, 2023
Credits: 1.25 CME / NCPD / CPE / IPCE
PVI, PeerView Institute for Medical Education
FcRn Modulation as a Targeted Approach to Myasthenia Gravis Management: From Pathophysiologic Rationale to Practical Application

FcRn Modulation as a Targeted Approach to Myasthenia Gravis Management: From Pathophysiologic Rationale to Practical Application

Start

FcRn Modulation as a Targeted Approach to Myasthenia Gravis Management: From Pathophysiologic Rationale to Practical Application

Media: Enduring Material
Activity Release Date: October 7, 2023
Activity Expiration Date: November 6, 2024
Time to Complete Activity: 75 minutes

Activity Description

Advances in the understanding of the pathogenesis of generalized myasthenia gravis (gMG), a rare, chronic autoimmune disorder, have led to the development of new therapeutics that more selectively address the underlying disease process compared with traditional therapies that often left patients with substantial disease and treatment burden. These newer treatments include Fc receptor (FcRn) inhibitors that increase immunoglobulin G (IgG) degradation, leading to reduced levels of autoreactive IgG antibodies via differing mechanisms of action and modes of delivery, including intravenous infusion and subcutaneous injection.

In this PeerView “Candid Conversations and Clinical Consults” activity, a neurologist, a clinical pharmacist, and an infusion nurse guide participants through a case-based look at the evolving gMG treatment landscape. The faculty share their expertise and put gMG management into practical context through panel discussions that reflect their unique professional perspectives as members of the gMG care team.

Target Audience

This activity has been designed to meet the educational needs of neurologists, nurse practitioners, pharmacists, infusion nurses, and other clinicians involved in the management of patients with myasthenia gravis.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Assess how the safety, efficacy, and tolerability data related to newer treatment options for generalized myasthenia gravis (gMG) compare with the corresponding data for traditionally used therapies
  • Demonstrate understanding of the rationale and mechanisms for reducing levels of autoreactive IgG antibodies using FcRn-modulating therapies when making gMG treatment decisions
  • Implement safe, individualized administration protocols for patients using FcRn-modulating therapy, with consideration for proper infusion procedures, premedications, vaccinations, and treatment cycle timing

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
James F. Howard Jr., MD
Professor of Neurology, Medicine and Allied Health
Department of Neurology
The University of North Carolina at Chapel Hill
Chapel Hill, North Carolina

James F. Howard Jr., MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Alexion Pharmaceuticals, Inc.; Argenx; Biologix Pharma; F. Hoffmann-La Roche Ltd.; Horizon Therapeutics plc; Immunovant, Inc.; Merck & Co., Inc./EMD Serono, Inc.; NMD Pharma A/S; Novartis Pharmaceuticals Corporation; Ra Pharmaceuticals, Inc./UCB Inc.; Regeneron Pharmaceuticals Inc.; Sanofi; Toleranzia AB; and Zai Lab.
Grant/Research Support from Alexion Pharmaceuticals, Inc.; Argenx; Cartesian Therapeutics, Inc.; and Ra Pharmaceuticals, Inc./UCB Inc.
Speaker for Alexion Pharmaceuticals, Inc.; Argenx; F. Hoffmann-La Roche Ltd; and Zai Lab.

Faculty/Planner
Amy Clarke, MSN, RN, IgCN
Vice President
Clinical Nursing Practice
Optum Infusion Pharmacy
Lenexa, Kansas

Amy Clarke, MSN, RN, IgCN, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Grifols, S.A.; Kedrion Biopharma Inc.; Koru Pharma Co., LTD; Pfizer; and Takeda Pharmaceutical Company Limited.

Faculty/Planner
Claire Spahn, PharmD, BCPS
Clinical Pharmacist in Neurology
Stanford Neuroscience Health Center
Stanford, California

Claire Spahn, PharmD, BCPS, has no financial interests/relationships or affiliations in relation to this activity.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by an educational grant from argenx US, Inc.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.25 contact hour(s) and 0.75 contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 1.25 contact hours (0.125 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-23-057-H01-P
Type of Activity: Application

Interprofessional Continuing Education (IPCE) Statement

IPCE This activity was planned by and for the healthcare team, and learners will receive 1.25 Interprofessional Continuing Education (IPCE) credits for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/NCPD/CPE/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2023, PeerView

FcRn Modulation as a Targeted Approach to Myasthenia Gravis Management: From Pathophysiologic Rationale to Practical Application

Media: Enduring Material
Activity Release Date: October 7, 2023
Activity Expiration Date: November 6, 2024
Time to Complete Activity: 75 minutes

Activity Description

Advances in the understanding of the pathogenesis of generalized myasthenia gravis (gMG), a rare, chronic autoimmune disorder, have led to the development of new therapeutics that more selectively address the underlying disease process compared with traditional therapies that often left patients with substantial disease and treatment burden. These newer treatments include Fc receptor (FcRn) inhibitors that increase immunoglobulin G (IgG) degradation, leading to reduced levels of autoreactive IgG antibodies via differing mechanisms of action and modes of delivery, including intravenous infusion and subcutaneous injection.

In this PeerView “Candid Conversations and Clinical Consults” activity, a neurologist, a clinical pharmacist, and an infusion nurse guide participants through a case-based look at the evolving gMG treatment landscape. The faculty share their expertise and put gMG management into practical context through panel discussions that reflect their unique professional perspectives as members of the gMG care team.

Target Audience

This activity has been designed to meet the educational needs of neurologists, nurse practitioners, pharmacists, infusion nurses, and other clinicians involved in the management of patients with myasthenia gravis.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Assess how the safety, efficacy, and tolerability data related to newer treatment options for generalized myasthenia gravis (gMG) compare with the corresponding data for traditionally used therapies
  • Demonstrate understanding of the rationale and mechanisms for reducing levels of autoreactive IgG antibodies using FcRn-modulating therapies when making gMG treatment decisions
  • Implement safe, individualized administration protocols for patients using FcRn-modulating therapy, with consideration for proper infusion procedures, premedications, vaccinations, and treatment cycle timing

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
James F. Howard Jr., MD
Professor of Neurology, Medicine and Allied Health
Department of Neurology
The University of North Carolina at Chapel Hill
Chapel Hill, North Carolina

James F. Howard Jr., MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Alexion Pharmaceuticals, Inc.; Argenx; Biologix Pharma; F. Hoffmann-La Roche Ltd.; Horizon Therapeutics plc; Immunovant, Inc.; Merck & Co., Inc./EMD Serono, Inc.; NMD Pharma A/S; Novartis Pharmaceuticals Corporation; Ra Pharmaceuticals, Inc./UCB Inc.; Regeneron Pharmaceuticals Inc.; Sanofi; Toleranzia AB; and Zai Lab.
Grant/Research Support from Alexion Pharmaceuticals, Inc.; Argenx; Cartesian Therapeutics, Inc.; and Ra Pharmaceuticals, Inc./UCB Inc.
Speaker for Alexion Pharmaceuticals, Inc.; Argenx; F. Hoffmann-La Roche Ltd; and Zai Lab.

Faculty/Planner
Amy Clarke, MSN, RN, IgCN
Vice President
Clinical Nursing Practice
Optum Infusion Pharmacy
Lenexa, Kansas

Amy Clarke, MSN, RN, IgCN, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Grifols, S.A.; Kedrion Biopharma Inc.; Koru Pharma Co., LTD; Pfizer; and Takeda Pharmaceutical Company Limited.

Faculty/Planner
Claire Spahn, PharmD, BCPS
Clinical Pharmacist in Neurology
Stanford Neuroscience Health Center
Stanford, California

Claire Spahn, PharmD, BCPS, has no financial interests/relationships or affiliations in relation to this activity.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by an educational grant from argenx US, Inc.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.25 contact hour(s) and 0.75 contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 1.25 contact hours (0.125 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-23-057-H01-P
Type of Activity: Application

Interprofessional Continuing Education (IPCE) Statement

IPCE This activity was planned by and for the healthcare team, and learners will receive 1.25 Interprofessional Continuing Education (IPCE) credits for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/NCPD/CPE/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2023, PeerView

October 06, 2023
Credits: 1.0 CME / MOC / NCPD / CPE / AAPA / IPCE
PVI, PeerView Institute for Medical Education
Command and Control MDS: New Science in MDS Management and Implications for Veteran-Centered Care

Command and Control MDS: New Science in MDS Management and Implications for Veteran-Centered Care

Start

Command and Control MDS: New Science in MDS Management and Implications for Veteran-Centered Care

Media: Enduring Material
Activity Release Date: September 29, 2023
Activity Expiration Date: October 28, 2024
Time to Complete Activity: 60 minutes

Activity Description

Learn how to command and control management of MDS for your patients, including veterans who may be suffering from symptoms tied to this challenging disorder, in this PeerView Clinical Consults activity recorded at the 2023 Association of VA Hematology/Oncology Annual Meeting. Two experts in the field use conversational case discussions to provide guidance on a personalized, team-centered approach to managing MDS and use real-world scenarios to clarify the complexities of lower-risk MDS diagnosis and risk stratification, while providing guidance on how to leverage new science to overcome challenges such as anemia and transfusion dependence. Access this activity today to accelerate your practice with better outcomes, and learn how recent developments have changed the current standard of care.

Target Audience

This activity has been designed to meet the educational needs of medical oncologists and hematologists, and other clinicians involved in the management of patients with MDS.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Summarize the symptomatology, molecular features, and risk factors associated with MDS that can inform modern diagnostic, prognostic, and management plans
  • Cite updated evidence supporting the use of innovative therapeutics for the risk-adapted management of MDS
  • Develop team-based, personalized management strategies for MDS that incorporate newer therapeutics, including for the frontline and subsequent management of LR-MDS with anemia
  • Implement team strategies to address dosing, safety, and drug delivery considerations in the MDS setting

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Co-Chair/Planner
Michael R. Savona, MD
Professor of Medicine and Cancer Biology
Beverly and George Rawlings Director of Hematology Research
Department of Internal Medicine
Vanderbilt University School of Medicine
Nashville, Tennessee

Michael R. Savona, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie; Bristol Myers Squibb; CTI BioPharma Corp.; Geron; Karyopharm; Novartis Pharmaceuticals Corporation; Ryvu Therapeutics; and Sierra Oncology, Inc.
Grant/Research Support from ALX Oncology Inc.; Astex Pharmaceuticals; Incyte Corporation; and Takeda Pharmaceutical Company Limited.
Stock Shareholder in Empath Biosciences; Karyopharm and Ryvu Therapeutics.
Other Financial or Material Support from Astex Pharmaceuticals for travel grant.

Co-Chair/Planner
Andrew M. Brunner, MD
Assistant Professor, Harvard Medical School
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Andrew M. Brunner, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Acceleron Pharma, Inc.; Bristol Myers Squibb; Gilead Sciences, Inc.; Keros Therapeutics; LAVA Therapeutics; Novartis Pharmaceuticals Corporation; Rigel Pharmaceuticals, Inc.; Taiho Pharmaceutical Co., Ltd.; and Takeda Pharmaceutical Company Limited.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported through an educational grant from Bristol Myers Squibb.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-23-063-H01-P
Type of Activity: Application

Physician Assistants

AAPA PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 10/28/2024. PAs should only claim credit commensurate with the extent of their participation.

Interprofessional Continuing Education (IPCE) Statement

IPCE This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD/CPE/AAPA/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2023, PeerView

Command and Control MDS: New Science in MDS Management and Implications for Veteran-Centered Care

Media: Enduring Material
Activity Release Date: September 29, 2023
Activity Expiration Date: October 28, 2024
Time to Complete Activity: 60 minutes

Activity Description

Learn how to command and control management of MDS for your patients, including veterans who may be suffering from symptoms tied to this challenging disorder, in this PeerView Clinical Consults activity recorded at the 2023 Association of VA Hematology/Oncology Annual Meeting. Two experts in the field use conversational case discussions to provide guidance on a personalized, team-centered approach to managing MDS and use real-world scenarios to clarify the complexities of lower-risk MDS diagnosis and risk stratification, while providing guidance on how to leverage new science to overcome challenges such as anemia and transfusion dependence. Access this activity today to accelerate your practice with better outcomes, and learn how recent developments have changed the current standard of care.

Target Audience

This activity has been designed to meet the educational needs of medical oncologists and hematologists, and other clinicians involved in the management of patients with MDS.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Summarize the symptomatology, molecular features, and risk factors associated with MDS that can inform modern diagnostic, prognostic, and management plans
  • Cite updated evidence supporting the use of innovative therapeutics for the risk-adapted management of MDS
  • Develop team-based, personalized management strategies for MDS that incorporate newer therapeutics, including for the frontline and subsequent management of LR-MDS with anemia
  • Implement team strategies to address dosing, safety, and drug delivery considerations in the MDS setting

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Co-Chair/Planner
Michael R. Savona, MD
Professor of Medicine and Cancer Biology
Beverly and George Rawlings Director of Hematology Research
Department of Internal Medicine
Vanderbilt University School of Medicine
Nashville, Tennessee

Michael R. Savona, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie; Bristol Myers Squibb; CTI BioPharma Corp.; Geron; Karyopharm; Novartis Pharmaceuticals Corporation; Ryvu Therapeutics; and Sierra Oncology, Inc.
Grant/Research Support from ALX Oncology Inc.; Astex Pharmaceuticals; Incyte Corporation; and Takeda Pharmaceutical Company Limited.
Stock Shareholder in Empath Biosciences; Karyopharm and Ryvu Therapeutics.
Other Financial or Material Support from Astex Pharmaceuticals for travel grant.

Co-Chair/Planner
Andrew M. Brunner, MD
Assistant Professor, Harvard Medical School
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Andrew M. Brunner, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Acceleron Pharma, Inc.; Bristol Myers Squibb; Gilead Sciences, Inc.; Keros Therapeutics; LAVA Therapeutics; Novartis Pharmaceuticals Corporation; Rigel Pharmaceuticals, Inc.; Taiho Pharmaceutical Co., Ltd.; and Takeda Pharmaceutical Company Limited.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported through an educational grant from Bristol Myers Squibb.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-23-063-H01-P
Type of Activity: Application

Physician Assistants

AAPA PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 10/28/2024. PAs should only claim credit commensurate with the extent of their participation.

Interprofessional Continuing Education (IPCE) Statement

IPCE This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD/CPE/AAPA/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2023, PeerView

September 28, 2023
Credits: 1.0 CME / MOC / CPE / AAPA / IPCE
PVI, PeerView Institute for Medical Education
Novel Targets for Management of Generalized Pustular Psoriasis: Utilizing a Team-Based Approach From Diagnosis to Treatment of Flares

Novel Targets for Management of Generalized Pustular Psoriasis: Utilizing a Team-Based Approach From Diagnosis to Treatment of Flares

Start

Novel Targets for Management of Generalized Pustular Psoriasis: Utilizing a Team-Based Approach From Diagnosis to Treatment of Flares

Media: Enduring Material
Activity Release Date: September 14, 2023
Activity Expiration Date: September 13, 2024
Time to Complete Activity: 60 minutes

Activity Description

How much do you know about the changing therapeutic landscape and the first FDA-approved treatment for generalized pustular psoriasis (GPP)? Test your knowledge and earn credit as you get the latest evidence and expert guidance on individualizing treatment plans for patients with GPP.

Target Audience

This activity has been designed to meet the educational needs of dermatologists, emergency medicine specialists, general practitioners, family physicians, NPs, PAs, pharmacists, and other healthcare professionals involved in the care of patients with generalized pustular psoriasis.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Accurately diagnose pustular psoriasis and assess the disease severity based on patient history and clinical manifestations
  • Identify pathophysiological differences among generalized pustular psoriasis (GPP) and plaque psoriasis
  • Evaluate novel biologic therapies for pustular psoriasis based on their efficacy, safety, and mechanism of action
  • Develop effective, individualized treatment strategies for patients with GPP through patient education and shared decision-making and a multidisciplinary team-based approach

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Faculty/Planner
Boni Elizabeth Elewski, MD
Professor and Chair of Dermatology
UAB/ The University of Alabama at Birmingham
Birmingham, Alabama

Boni Elizabeth Elewski, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Amgen Inc.; Arcutis Biotherapeutics, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Janssen Pharmaceuticals, Inc.; LEO Pharma Inc.; Lilly; Novartis Pharmaceuticals Corporation; Ortho Dermatology; and UCB, Inc.
Grant/Research Support from AbbVie Inc.; AnaptysBio, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Incyte; Janssen Pharmaceuticals, Inc.; LEO Pharma Inc.; Lilly; Novartis Pharmaceuticals Corporation; Pfizer; and UCB, Inc.
Honoraria from Amgen Inc.; Arcutis Biotherapeutics, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Janssen Pharmaceuticals, Inc.; LEO Pharma Inc.; Lilly; Novartis Pharmaceuticals Corporation; Ortho Dermatology; and UCB, Inc.

Faculty/Planner
Mark Lebwohl, MD
Dean for Clinical Therapeutics
Professor & Chair Emeritus
Kimberly & Eric J. Waldman Department of Dermatology
Icahn School of Medicine
New York, New York

Mark Lebwohl, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AnaptysBio, Inc.; Almirall, LLC; AltruBio; AnaptysBio, Inc.; Apogee Therapeutics; Arcutis Biotherapeutics, Inc.; Aristea Therapeutics; Atomwise Inc.; Avotres Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Brickell Biotech; Bristol Myers Squibb; Cara Therapeutics; Castle Biosciences, Inc.; Celltrion, Inc.; CorEvitas, LLC; Dermavant Sciences, Inc.; Dr.Reddy’s; EPI Health; Evommune, Inc.; Facilitation of International Dermatology Education; Forte Biosciences, Inc.; Foundation for Research and Education in Dermatology; Galderma; Genentech, Inc.; Helsinn Healthcare S.A.; Incyte; LEO Pharma Inc.; Meiji Seika Kaisha, Ltd.; Mindera Health; National Society of Cutaneous Medicine; Pfizer; Seanergy Dermatology Ltd; Strata; Trevi Therapeutics; Verrica Pharmaceuticals; and Vial.
Grant/Research Support from AbbVie Inc.; Amgen Inc.; Arcutis Biotherapeutics, Inc.; Avotres Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Cara Therapeutics; Dermavant Sciences, Inc.; Incyte; Janssen Pharmaceuticals, Inc.; Lilly; Ortho Dermatologics; Regeneron Pharmaceuticals Inc.; and UCB, Inc.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-23-055-H01-P
Type of Activity: Knowledge

Physician Assistants

AAPA PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 9/13/2024. PAs should only claim credit commensurate with the extent of their participation.

Interprofessional Continuing Education (IPCE) Statement

IPCE This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is needed to obtain MOC/CC credit.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/CPE/AAPA/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2023, PeerView

Novel Targets for Management of Generalized Pustular Psoriasis: Utilizing a Team-Based Approach From Diagnosis to Treatment of Flares

Media: Enduring Material
Activity Release Date: September 14, 2023
Activity Expiration Date: September 13, 2024
Time to Complete Activity: 60 minutes

Activity Description

How much do you know about the changing therapeutic landscape and the first FDA-approved treatment for generalized pustular psoriasis (GPP)? Test your knowledge and earn credit as you get the latest evidence and expert guidance on individualizing treatment plans for patients with GPP.

Target Audience

This activity has been designed to meet the educational needs of dermatologists, emergency medicine specialists, general practitioners, family physicians, NPs, PAs, pharmacists, and other healthcare professionals involved in the care of patients with generalized pustular psoriasis.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Accurately diagnose pustular psoriasis and assess the disease severity based on patient history and clinical manifestations
  • Identify pathophysiological differences among generalized pustular psoriasis (GPP) and plaque psoriasis
  • Evaluate novel biologic therapies for pustular psoriasis based on their efficacy, safety, and mechanism of action
  • Develop effective, individualized treatment strategies for patients with GPP through patient education and shared decision-making and a multidisciplinary team-based approach

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Faculty/Planner
Boni Elizabeth Elewski, MD
Professor and Chair of Dermatology
UAB/ The University of Alabama at Birmingham
Birmingham, Alabama

Boni Elizabeth Elewski, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Amgen Inc.; Arcutis Biotherapeutics, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Janssen Pharmaceuticals, Inc.; LEO Pharma Inc.; Lilly; Novartis Pharmaceuticals Corporation; Ortho Dermatology; and UCB, Inc.
Grant/Research Support from AbbVie Inc.; AnaptysBio, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Incyte; Janssen Pharmaceuticals, Inc.; LEO Pharma Inc.; Lilly; Novartis Pharmaceuticals Corporation; Pfizer; and UCB, Inc.
Honoraria from Amgen Inc.; Arcutis Biotherapeutics, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Janssen Pharmaceuticals, Inc.; LEO Pharma Inc.; Lilly; Novartis Pharmaceuticals Corporation; Ortho Dermatology; and UCB, Inc.

Faculty/Planner
Mark Lebwohl, MD
Dean for Clinical Therapeutics
Professor & Chair Emeritus
Kimberly & Eric J. Waldman Department of Dermatology
Icahn School of Medicine
New York, New York

Mark Lebwohl, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AnaptysBio, Inc.; Almirall, LLC; AltruBio; AnaptysBio, Inc.; Apogee Therapeutics; Arcutis Biotherapeutics, Inc.; Aristea Therapeutics; Atomwise Inc.; Avotres Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Brickell Biotech; Bristol Myers Squibb; Cara Therapeutics; Castle Biosciences, Inc.; Celltrion, Inc.; CorEvitas, LLC; Dermavant Sciences, Inc.; Dr.Reddy’s; EPI Health; Evommune, Inc.; Facilitation of International Dermatology Education; Forte Biosciences, Inc.; Foundation for Research and Education in Dermatology; Galderma; Genentech, Inc.; Helsinn Healthcare S.A.; Incyte; LEO Pharma Inc.; Meiji Seika Kaisha, Ltd.; Mindera Health; National Society of Cutaneous Medicine; Pfizer; Seanergy Dermatology Ltd; Strata; Trevi Therapeutics; Verrica Pharmaceuticals; and Vial.
Grant/Research Support from AbbVie Inc.; Amgen Inc.; Arcutis Biotherapeutics, Inc.; Avotres Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Cara Therapeutics; Dermavant Sciences, Inc.; Incyte; Janssen Pharmaceuticals, Inc.; Lilly; Ortho Dermatologics; Regeneron Pharmaceuticals Inc.; and UCB, Inc.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-23-055-H01-P
Type of Activity: Knowledge

Physician Assistants

AAPA PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 9/13/2024. PAs should only claim credit commensurate with the extent of their participation.

Interprofessional Continuing Education (IPCE) Statement

IPCE This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is needed to obtain MOC/CC credit.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/CPE/AAPA/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2023, PeerView

September 14, 2023
Credits: 1.0 CME / MOC / NCPD / CPE
Medical Learning Institute, Inc.
The Commanding Heights of MDS Care: Team Strategies for Delivering Modern Personalized Therapy

The Commanding Heights of MDS Care: Team Strategies for Delivering Modern Personalized Therapy

Start

The Commanding Heights of MDS Care: Team Strategies for Delivering Modern Personalized Therapy

Media: Enduring Material
Activity Release Date: September 7, 2023
Activity Expiration Date: October 6, 2024
Time to Complete Activity: 60 minutes

Activity Description

Myelodysplastic syndromes (MDS) encompass a diverse group of myeloid malignancies, and new data are changing what can be considered “optimal” care. In this “Seminar and Workshop” activity, two hematology-oncology experts employ case-centric discussions to provide experienced instruction on the changing nature of individualized care for patients with MDS. This activity includes updated evidence supporting the use of innovative therapies for first-line management of MDS anemia, how to treat patients with ESA-refractory MDS, and treatment strategies for individuals presenting with high-risk mutations or cytogenetics. Watch now and take your treatment plans for patients with MDS to new heights!

Target Audience

This activity has been designed to meet the educational needs of hematologist-oncologists, hematologists, nurses, pharmacists, advanced practice clinicians (including hematology-oncology NPs and PAs), and other team-based clinicians involved in the management of MDS.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Cite clinical, cytogenetic, and molecular features that can inform timely, accurate diagnosis and prognosis in the MDS setting
  • Describe the evidence that supports the use of innovative therapeutics, including erythroid maturation agents, telomerase inhibitors, hypomethylating agent platforms, BCL2 inhibitors, and immunotherapy, in the management of patients with low-risk or high-risk MDS
  • Develop personalized MDS treatment protocols for the first-line management of anemia, in the ESA-refractory setting, and for patients presenting with high-risk MDS subtypes
  • Address practical aspects of modern MDS therapy, including appropriate dose selection, response monitoring, and therapy-related adverse events management

Accreditation, Support, and Credit


JAP In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This educational activity is supported through educational grants from Bristol Myers Squibb, Geron, and Novartis Pharmaceuticals Corporation.

Physician Continuing Medical Education

Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nursing Continuing Professional Development

Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour(s) and 0.75 contact hour(s) in the area of pharmacology.

Continuing Pharmacy Education

Medical Learning Institute, Inc. designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA0007322-0000-23-088-H01-P
Type of Activity: Knowledge

Faculty Disclosures

Co-Chair/Planner
Guillermo Garcia-Manero, MD
McCredie Professor of Medicine
Chief, Section of MDS
Vice Chair, Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas

Guillermo Garcia-Manero, MD, has no financial interests/relationships or affiliations in relation to this activity.

Co-Chair/Planner
Amy E. DeZern, MD, MHS
Professor of Oncology
Division of Hematologic Malignancies
Sidney Kimmel Comprehensive Cancer Center
The Johns Hopkins University School of Medicine
Baltimore, Maryland

Amy E. DeZern, MD, MHS, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Bristol Myers Squibb; Caribou Biosciences; Geron; Gilead Sciences, Inc.; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals; and Sobi.

All of the relevant financial relationships listed have been mitigated.

Planning Committee and Content/Peer Reviewers

The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, and PVI, PeerView Institute for Medical Education, our educational partner, do not have any relevant financial relationship(s) to disclose with ineligible companies unless listed below.

Disclosure of Unlabeled Use

This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

In order to receive credit, learners must participate in the entire CE activity. A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 70% or higher is needed to obtain MOC/CC credit (75% is required for ABS).

For nurses, the post-test and evaluation are required in their entirety and a score of 70% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) contact hours.

For pharmacists, upon receipt of the completed activity evaluation, you will receive an email from email@email.peerviewpress.com within 2 weeks. MLI will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and DOB (MM/DD). Within 6 weeks, you can view your participation record at the NABP website: https://nabp.pharmacy/.

About This CME/MOC/NCPD/CPE Activity

PVI, PeerView Institute for Medical Education, and Medical Learning Institute, Inc. are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Medical Learning Institute, Inc.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

Copyright © 2000-2023, PeerView

The Commanding Heights of MDS Care: Team Strategies for Delivering Modern Personalized Therapy

Media: Enduring Material
Activity Release Date: September 7, 2023
Activity Expiration Date: October 6, 2024
Time to Complete Activity: 60 minutes

Activity Description

Myelodysplastic syndromes (MDS) encompass a diverse group of myeloid malignancies, and new data are changing what can be considered “optimal” care. In this “Seminar and Workshop” activity, two hematology-oncology experts employ case-centric discussions to provide experienced instruction on the changing nature of individualized care for patients with MDS. This activity includes updated evidence supporting the use of innovative therapies for first-line management of MDS anemia, how to treat patients with ESA-refractory MDS, and treatment strategies for individuals presenting with high-risk mutations or cytogenetics. Watch now and take your treatment plans for patients with MDS to new heights!

Target Audience

This activity has been designed to meet the educational needs of hematologist-oncologists, hematologists, nurses, pharmacists, advanced practice clinicians (including hematology-oncology NPs and PAs), and other team-based clinicians involved in the management of MDS.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Cite clinical, cytogenetic, and molecular features that can inform timely, accurate diagnosis and prognosis in the MDS setting
  • Describe the evidence that supports the use of innovative therapeutics, including erythroid maturation agents, telomerase inhibitors, hypomethylating agent platforms, BCL2 inhibitors, and immunotherapy, in the management of patients with low-risk or high-risk MDS
  • Develop personalized MDS treatment protocols for the first-line management of anemia, in the ESA-refractory setting, and for patients presenting with high-risk MDS subtypes
  • Address practical aspects of modern MDS therapy, including appropriate dose selection, response monitoring, and therapy-related adverse events management

Accreditation, Support, and Credit


JAP In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This educational activity is supported through educational grants from Bristol Myers Squibb, Geron, and Novartis Pharmaceuticals Corporation.

Physician Continuing Medical Education

Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nursing Continuing Professional Development

Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour(s) and 0.75 contact hour(s) in the area of pharmacology.

Continuing Pharmacy Education

Medical Learning Institute, Inc. designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA0007322-0000-23-088-H01-P
Type of Activity: Knowledge

Faculty Disclosures

Co-Chair/Planner
Guillermo Garcia-Manero, MD
McCredie Professor of Medicine
Chief, Section of MDS
Vice Chair, Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas

Guillermo Garcia-Manero, MD, has no financial interests/relationships or affiliations in relation to this activity.

Co-Chair/Planner
Amy E. DeZern, MD, MHS
Professor of Oncology
Division of Hematologic Malignancies
Sidney Kimmel Comprehensive Cancer Center
The Johns Hopkins University School of Medicine
Baltimore, Maryland

Amy E. DeZern, MD, MHS, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Bristol Myers Squibb; Caribou Biosciences; Geron; Gilead Sciences, Inc.; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals; and Sobi.

All of the relevant financial relationships listed have been mitigated.

Planning Committee and Content/Peer Reviewers

The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, and PVI, PeerView Institute for Medical Education, our educational partner, do not have any relevant financial relationship(s) to disclose with ineligible companies unless listed below.

Disclosure of Unlabeled Use

This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

In order to receive credit, learners must participate in the entire CE activity. A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 70% or higher is needed to obtain MOC/CC credit (75% is required for ABS).

For nurses, the post-test and evaluation are required in their entirety and a score of 70% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) contact hours.

For pharmacists, upon receipt of the completed activity evaluation, you will receive an email from email@email.peerviewpress.com within 2 weeks. MLI will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and DOB (MM/DD). Within 6 weeks, you can view your participation record at the NABP website: https://nabp.pharmacy/.

About This CME/MOC/NCPD/CPE Activity

PVI, PeerView Institute for Medical Education, and Medical Learning Institute, Inc. are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Medical Learning Institute, Inc.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

Copyright © 2000-2023, PeerView

September 06, 2023
Credits: 1.0 CME / MOC / NCPD / CPE
Medical Learning Institute, Inc.
Level Up With Personalized Care for CLL/SLL: Achieving Better Total Care With Targeted Agents & Innovative Combinations

Level Up With Personalized Care for CLL/SLL: Achieving Better Total Care With Targeted Agents & Innovative Combinations

Start

Level Up With Personalized Care for CLL/SLL: Achieving Better Total Care With Targeted Agents & Innovative Combinations

Media: Enduring Material
Activity Release Date: September 7, 2023
Activity Expiration Date: October 6, 2024
Time to Complete Activity: 60 minutes

Activity Description

Innovative therapeutics have transformed the management of chronic lymphocytic leukemia (CLL) and allowed patients a greater range of treatment options. Covalent BTK inhibitors (BTKi) and BCL2 inhibitors (BCL2i) have demonstrated efficacy in a wide variety of treatment settings, and newer, non-covalent BTKi are poised to overcome long-standing therapeutic standards. Do you have the tools needed to “level up” your practice?

Find out in this “Clinical Consults” activity based on a symposium that was recorded at the Society of Hematologic Oncology’s 11th Annual Meeting. Throughout this program, a panel of leading CLL experts use conversational, case-based dialogue to provide guidance on integrating modern therapeutics anchored by BTKi and BCL2i regimens, along with rapidly emerging non-covalent BTKi and BTKi-BCL2i combinations. Join the leading lights of CLL, sharpen your therapeutic skills, and reach the next level of CLL care today!

Target Audience

This activity has been designed to meet the educational needs of hematologist-oncologists, hematologists, nurses, pharmacists, advanced practice clinicians (including hematology-oncology NPs and PAs), and other clinicians involved in the management of CLL.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Cite current evidence and updated practice guidelines supporting the use of targeted agents and emerging treatment options in CLL, such as BTK and BCL2 inhibitors, CAR-T, and bispecifics
  • Develop personalized management protocols that include established and emerging targeted strategies as single-agent and combination platforms for patients with treatment-naïve CLL based on prognostic information, the presence of comorbidities, and safety considerations
  • Implement sequential treatment plans with targeted options for patients with therapeutic intolerance and/or relapsed/refractory CLL
  • Manage safety and care delivery considerations associated with the use of targeted agents and other newer therapeutics in the CLL setting

Accreditation, Support, and Credit

JAP In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by independent educational grants from AstraZeneca; BeiGene; Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; and Lilly.

Physician Continuing Medical Education

Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nursing Continuing Professional Development

Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.

Continuing Pharmacy Education

Medical Learning Institute, Inc. designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA0007322-0000-23-089-H01-P
Type of Activity: Application

Faculty Disclosures

Co-Chair/Planner
William G. Wierda, MD, PhD
Professor, Department of Leukemia, Division of Cancer Medicine
Jane and John Justin Distinguished Chair in Leukemia Research in Honor of Dr. Elihu Estey
Section Chief - Chronic Lymphocytic Leukemia
Center Medical Director, Leukemia
Executive Medical Director, Inpatient Medical Services
The University of Texas MD Anderson Cancer Center
Houston, Texas

William G. Wierda, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Grant/Research Support from AbbVie; Acerta Pharma; Accutar Biotech; Bristol Myers Squibb; Cyclacel Pharmaceuticals Inc.; Genentech, Inc.; Gilead Sciences, Inc.; GlaxoSmithKline; Janssen Biotech, Inc.; Juno Pharmaceuticals; Kite, A Gilead Company; Loxo Oncology, Inc.; miRagen Therapeutics, Inc. (ended); Novartis Pharmaceuticals Corporation; Numab Therapeutics AG; Nurix Therapeutics, Inc.; Oncternal Therapeutics; Pharmacyclics, Inc.; Sunesis Pharmaceuticals, Inc. (ended); and Xencor.
Other Financial or Material Support for Nonrelevant Financial Relationship: National Comprehensive Cancer Network (Chair & CLL); NIH/NCI under award number P30 CA016672 and used MDACC Cancer Center Support Grant (CCSG) shared resources.

Co-Chair/Planner
Nicole Lamanna, MD
Professor of Medicine, Leukemia Service
Director of the Chronic Lymphocytic Leukemia Program
Hematologic Malignancies Section
Herbert Irving Comprehensive Cancer Center
New York-Presbyterian/Columbia University Medical Center
New York, New York

Nicole Lamanna, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie; Adaptive Biotechnologies; AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; and Pharmacyclics LLC.
Grant/Research Support from AbbVie; AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Lilly/Loxo Oncology; MingSight Pharmaceuticals, Inc.; Octapharma USA, Inc.; Oncternal Therapeutics; and TG Therapeutics, Inc.

Faculty/Planner
Meghan C. Thompson, MD
Assistant Attending L1, Leukemia Service
Memorial Sloan Kettering Cancer Center
New York, New York

Meghan C. Thompson, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Lilly/LOXO Oncology; Janssen Pharmaceuticals, Inc.; and Pharmacyclics LLC.
Grant/Research Support from AbbVie; AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Genmab; and Nurix Therapeutics. Research funding goes to Institution.
Honoraria from Brazilian Association of Hematology; Dava Oncology; Curio Science; Hemotherapy and Cellular Therapy (ABHH); Massachusetts Medical Society; MJH Life Sciences; Intellisphere LLC; Phillips Group Oncology Communications; and VJHemOnc.

All of the relevant financial relationships listed have been mitigated.

Planning Committee and Content/Peer Reviewers

The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, and PVI, PeerView Institute for Medical Education, our educational partner, do not have any relevant financial relationship(s) to disclose with ineligible companies unless listed below.

Disclosure of Unlabeled Use

This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

In order to receive credit, learners must participate in the entire CE activity. A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 70% or higher is needed to obtain MOC/CC credit (75% is required for ABS).

For nurses, the post-test and evaluation are required in their entirety and a score of 70% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) contact hours.

For pharmacists, upon receipt of the completed activity evaluation, you will receive an email from email@email.peerviewpress.com within 2 weeks. MLI will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and DOB (MM/DD). Within 6 weeks, you can view your participation record at the NABP website: https://nabp.pharmacy/.

About This CME/MOC/NCPD/CPE Activity

PVI, PeerView Institute for Medical Education, and Medical Learning Institute, Inc. are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Medical Learning Institute, Inc.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

Copyright © 2000-2023, PeerView

Level Up With Personalized Care for CLL/SLL: Achieving Better Total Care With Targeted Agents & Innovative Combinations

Media: Enduring Material
Activity Release Date: September 7, 2023
Activity Expiration Date: October 6, 2024
Time to Complete Activity: 60 minutes

Activity Description

Innovative therapeutics have transformed the management of chronic lymphocytic leukemia (CLL) and allowed patients a greater range of treatment options. Covalent BTK inhibitors (BTKi) and BCL2 inhibitors (BCL2i) have demonstrated efficacy in a wide variety of treatment settings, and newer, non-covalent BTKi are poised to overcome long-standing therapeutic standards. Do you have the tools needed to “level up” your practice?

Find out in this “Clinical Consults” activity based on a symposium that was recorded at the Society of Hematologic Oncology’s 11th Annual Meeting. Throughout this program, a panel of leading CLL experts use conversational, case-based dialogue to provide guidance on integrating modern therapeutics anchored by BTKi and BCL2i regimens, along with rapidly emerging non-covalent BTKi and BTKi-BCL2i combinations. Join the leading lights of CLL, sharpen your therapeutic skills, and reach the next level of CLL care today!

Target Audience

This activity has been designed to meet the educational needs of hematologist-oncologists, hematologists, nurses, pharmacists, advanced practice clinicians (including hematology-oncology NPs and PAs), and other clinicians involved in the management of CLL.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Cite current evidence and updated practice guidelines supporting the use of targeted agents and emerging treatment options in CLL, such as BTK and BCL2 inhibitors, CAR-T, and bispecifics
  • Develop personalized management protocols that include established and emerging targeted strategies as single-agent and combination platforms for patients with treatment-naïve CLL based on prognostic information, the presence of comorbidities, and safety considerations
  • Implement sequential treatment plans with targeted options for patients with therapeutic intolerance and/or relapsed/refractory CLL
  • Manage safety and care delivery considerations associated with the use of targeted agents and other newer therapeutics in the CLL setting

Accreditation, Support, and Credit

JAP In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by independent educational grants from AstraZeneca; BeiGene; Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; and Lilly.

Physician Continuing Medical Education

Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nursing Continuing Professional Development

Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.

Continuing Pharmacy Education

Medical Learning Institute, Inc. designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA0007322-0000-23-089-H01-P
Type of Activity: Application

Faculty Disclosures

Co-Chair/Planner
William G. Wierda, MD, PhD
Professor, Department of Leukemia, Division of Cancer Medicine
Jane and John Justin Distinguished Chair in Leukemia Research in Honor of Dr. Elihu Estey
Section Chief - Chronic Lymphocytic Leukemia
Center Medical Director, Leukemia
Executive Medical Director, Inpatient Medical Services
The University of Texas MD Anderson Cancer Center
Houston, Texas

William G. Wierda, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Grant/Research Support from AbbVie; Acerta Pharma; Accutar Biotech; Bristol Myers Squibb; Cyclacel Pharmaceuticals Inc.; Genentech, Inc.; Gilead Sciences, Inc.; GlaxoSmithKline; Janssen Biotech, Inc.; Juno Pharmaceuticals; Kite, A Gilead Company; Loxo Oncology, Inc.; miRagen Therapeutics, Inc. (ended); Novartis Pharmaceuticals Corporation; Numab Therapeutics AG; Nurix Therapeutics, Inc.; Oncternal Therapeutics; Pharmacyclics, Inc.; Sunesis Pharmaceuticals, Inc. (ended); and Xencor.
Other Financial or Material Support for Nonrelevant Financial Relationship: National Comprehensive Cancer Network (Chair & CLL); NIH/NCI under award number P30 CA016672 and used MDACC Cancer Center Support Grant (CCSG) shared resources.

Co-Chair/Planner
Nicole Lamanna, MD
Professor of Medicine, Leukemia Service
Director of the Chronic Lymphocytic Leukemia Program
Hematologic Malignancies Section
Herbert Irving Comprehensive Cancer Center
New York-Presbyterian/Columbia University Medical Center
New York, New York

Nicole Lamanna, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie; Adaptive Biotechnologies; AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; and Pharmacyclics LLC.
Grant/Research Support from AbbVie; AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Lilly/Loxo Oncology; MingSight Pharmaceuticals, Inc.; Octapharma USA, Inc.; Oncternal Therapeutics; and TG Therapeutics, Inc.

Faculty/Planner
Meghan C. Thompson, MD
Assistant Attending L1, Leukemia Service
Memorial Sloan Kettering Cancer Center
New York, New York

Meghan C. Thompson, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Lilly/LOXO Oncology; Janssen Pharmaceuticals, Inc.; and Pharmacyclics LLC.
Grant/Research Support from AbbVie; AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Genmab; and Nurix Therapeutics. Research funding goes to Institution.
Honoraria from Brazilian Association of Hematology; Dava Oncology; Curio Science; Hemotherapy and Cellular Therapy (ABHH); Massachusetts Medical Society; MJH Life Sciences; Intellisphere LLC; Phillips Group Oncology Communications; and VJHemOnc.

All of the relevant financial relationships listed have been mitigated.

Planning Committee and Content/Peer Reviewers

The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, and PVI, PeerView Institute for Medical Education, our educational partner, do not have any relevant financial relationship(s) to disclose with ineligible companies unless listed below.

Disclosure of Unlabeled Use

This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

In order to receive credit, learners must participate in the entire CE activity. A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 70% or higher is needed to obtain MOC/CC credit (75% is required for ABS).

For nurses, the post-test and evaluation are required in their entirety and a score of 70% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) contact hours.

For pharmacists, upon receipt of the completed activity evaluation, you will receive an email from email@email.peerviewpress.com within 2 weeks. MLI will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and DOB (MM/DD). Within 6 weeks, you can view your participation record at the NABP website: https://nabp.pharmacy/.

About This CME/MOC/NCPD/CPE Activity

PVI, PeerView Institute for Medical Education, and Medical Learning Institute, Inc. are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Medical Learning Institute, Inc.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

Copyright © 2000-2023, PeerView

September 06, 2023
Credits: 1.0 CME / MOC / NCPD / CPE
Medical Learning Institute, Inc.
Expanding the Circle of Personalized AML Treatment: Expert Consults on Integrating Precision Medicine With Innovative Treatment Platforms

Expanding the Circle of Personalized AML Treatment: Expert Consults on Integrating Precision Medicine With Innovative Treatment Platforms

Start

Expanding the Circle of Personalized AML Treatment: Expert Consults on Integrating Precision Medicine With Innovative Treatment Platforms

Media: Enduring Material
Activity Release Date: September 7, 2023
Activity Expiration Date: October 6, 2024
Time to Complete Activity: 60 minutes

Activity Description

In recent years, the “circle” of personalized disease management for acute myeloid leukemia (AML) has been expanded, and clinicians are now able to utilize innovative therapeutics, such as novel cytotoxic platforms, targeted agents, immunotherapy, and epigenetic approaches, that can be tailored to patients’ diverse medical needs. This Clinical Consults activity pairs rapid-fire, case-based discussions with mini lecture sessions wherein the experts support their treatment recommendations by presenting the evidence that supports the use of cutting-edge therapeutics—including newer FLT3 inhibitors, chemo-free targeted platforms, epigenetic agents, and emerging antibody platforms —in various AML settings. Join the experts and learn how you can successfully “expand the circle” of personalized care in AML!

Target Audience

This activity has been designed to meet the educational needs of hematologist-oncologists, hematologists, nurses, pharmacists, advanced practice clinicians (including hematology-oncology NPs and PAs), and other clinicians involved in the management of AML.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Cite baseline factors such as age, comorbidities, functional status, and cytogenetic/mutational findings that can inform personalized treatment selection in AML
  • Describe evidence supporting the personalized use of newer cytotoxic platforms, targeted agents, immunotherapy, radioimmunoconjugates, and epigenetic strategies as upfront treatment, maintenance therapy, or in the management of R/R AML
  • Develop personalized team-based management protocols for AML that integrate newer treatment modalities based on the presence or absence of targetable mutations, functional status, treatment setting, or subtype
  • Manage optimized dosing, response monitoring, and safety considerations when using modern therapeutic platforms in the AML setting

Accreditation, Support, and Credit

JAP In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported through educational grants from Actinium Pharmaceuticals, Astellas, and Bristol Myers Squibb.

Physician Continuing Medical Education

Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nursing Continuing Professional Development

Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.

Continuing Pharmacy Education

Medical Learning Institute, Inc. designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA0007322-0000-23-091-H01-P
Type of Activity: Application

Faculty Disclosures

Co-Chair/Planner
Naval Daver, MD
Director, Leukemia Research Alliance Program
Professor
Department of Leukemia, Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas

Naval Daver, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie; Agios Pharmaceuticals, Inc.; Amgen Inc.; AROG Pharmaceuticals, INC.; Astellas Pharma Inc.; Bristol Myers Squibb; Celgene Corporation; Daiichi Sankyo, Inc.; Genentech, Inc.; Gilead Sciences, Inc.; ImmunoGen, Inc.; Jazz Pharmaceuticals, Inc.; Kite, A Gilead Company; Novartis Pharmaceuticals Corporation; Pfizer; Servier Pharmaceuticals LLC; Shattuck Labs, Inc.; Stemline Therapeutics/Menarini Group; Syndax Pharmaceuticals Inc.; and Trillium Therapeutics Inc.
Grant/Research Support from AbbVie; Amgen Inc.; Astellas Pharma Inc.; Bristol Myers Squibb; Daiichi Sankyo, Inc.; Fate Therapeutics; Genentech, Inc.; Gilead Sciences, Inc.; GlycoMimetics, Inc.; Hanmi Pharmaceutical Co., Ltd.; ImmunoGen, Inc.; Kite, A Gilead Company; NovImmune SA; Pfizer; Servier Pharmaceuticals LLC; Trillium Therapeutics Inc.; and TrovaGene, Inc. Research funding goes to institution.

Co-Chair/Planner
Gail J. Roboz, MD
William S. Paley Professor of Medicine
Director, Clinical and Translational Leukemia Programs
Weill Cornell Medicine
The New York Presbyterian Hospital
New York, New York

Gail J. Roboz, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie; Amgen Inc.; Argenx; AstraZeneca; bluebird bio, Inc.; Blueprint Medicines; Bristol Myers Squibb; Caribou Biosciences; Celgene Corporation; Daiichi Sankyo, Inc.; Ellipses Pharma; F. Hoffmann-La Roche AG; GlaxoSmithKline; Janssen Pharmaceuticals, Inc; Jasper Therapeutics, Inc.; Jazz Pharmaceuticals, Inc.; Molecular Partners; Novartis Pharmaceuticals Corporation; Pfizer; Syndax Pharmaceuticals Inc.; Takeda Pharmaceutical Company Limited (IRC Chair); and Telix Pharma.
Grant/Research Support from Janssen Pharmaceuticals, Inc.

All of the relevant financial relationships listed have been mitigated.

Planning Committee and Content/Peer Reviewers

The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, and PVI, PeerView Institute for Medical Education, our educational partner, do not have any relevant financial relationship(s) to disclose with ineligible companies unless listed below.

Disclosure of Unlabeled Use

This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

In order to receive credit, learners must participate in the entire CE activity. A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 70% or higher is needed to obtain MOC/CC credit (75% is required for ABS).

For nurses, the post-test and evaluation are required in their entirety and a score of 70% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) contact hours.

For pharmacists, upon receipt of the completed activity evaluation, you will receive an email from email@email.peerviewpress.com within 2 weeks. MLI will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and DOB (MM/DD). Within 6 weeks, you can view your participation record at the NABP website: https://nabp.pharmacy/.

About This CME/MOC/NCPD/CPE Activity

PVI, PeerView Institute for Medical Education, and Medical Learning Institute, Inc. are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Medical Learning Institute, Inc.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

Copyright © 2000-2023, PeerView

Expanding the Circle of Personalized AML Treatment: Expert Consults on Integrating Precision Medicine With Innovative Treatment Platforms

Media: Enduring Material
Activity Release Date: September 7, 2023
Activity Expiration Date: October 6, 2024
Time to Complete Activity: 60 minutes

Activity Description

In recent years, the “circle” of personalized disease management for acute myeloid leukemia (AML) has been expanded, and clinicians are now able to utilize innovative therapeutics, such as novel cytotoxic platforms, targeted agents, immunotherapy, and epigenetic approaches, that can be tailored to patients’ diverse medical needs. This Clinical Consults activity pairs rapid-fire, case-based discussions with mini lecture sessions wherein the experts support their treatment recommendations by presenting the evidence that supports the use of cutting-edge therapeutics—including newer FLT3 inhibitors, chemo-free targeted platforms, epigenetic agents, and emerging antibody platforms —in various AML settings. Join the experts and learn how you can successfully “expand the circle” of personalized care in AML!

Target Audience

This activity has been designed to meet the educational needs of hematologist-oncologists, hematologists, nurses, pharmacists, advanced practice clinicians (including hematology-oncology NPs and PAs), and other clinicians involved in the management of AML.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Cite baseline factors such as age, comorbidities, functional status, and cytogenetic/mutational findings that can inform personalized treatment selection in AML
  • Describe evidence supporting the personalized use of newer cytotoxic platforms, targeted agents, immunotherapy, radioimmunoconjugates, and epigenetic strategies as upfront treatment, maintenance therapy, or in the management of R/R AML
  • Develop personalized team-based management protocols for AML that integrate newer treatment modalities based on the presence or absence of targetable mutations, functional status, treatment setting, or subtype
  • Manage optimized dosing, response monitoring, and safety considerations when using modern therapeutic platforms in the AML setting

Accreditation, Support, and Credit

JAP In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported through educational grants from Actinium Pharmaceuticals, Astellas, and Bristol Myers Squibb.

Physician Continuing Medical Education

Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nursing Continuing Professional Development

Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.

Continuing Pharmacy Education

Medical Learning Institute, Inc. designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA0007322-0000-23-091-H01-P
Type of Activity: Application

Faculty Disclosures

Co-Chair/Planner
Naval Daver, MD
Director, Leukemia Research Alliance Program
Professor
Department of Leukemia, Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas

Naval Daver, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie; Agios Pharmaceuticals, Inc.; Amgen Inc.; AROG Pharmaceuticals, INC.; Astellas Pharma Inc.; Bristol Myers Squibb; Celgene Corporation; Daiichi Sankyo, Inc.; Genentech, Inc.; Gilead Sciences, Inc.; ImmunoGen, Inc.; Jazz Pharmaceuticals, Inc.; Kite, A Gilead Company; Novartis Pharmaceuticals Corporation; Pfizer; Servier Pharmaceuticals LLC; Shattuck Labs, Inc.; Stemline Therapeutics/Menarini Group; Syndax Pharmaceuticals Inc.; and Trillium Therapeutics Inc.
Grant/Research Support from AbbVie; Amgen Inc.; Astellas Pharma Inc.; Bristol Myers Squibb; Daiichi Sankyo, Inc.; Fate Therapeutics; Genentech, Inc.; Gilead Sciences, Inc.; GlycoMimetics, Inc.; Hanmi Pharmaceutical Co., Ltd.; ImmunoGen, Inc.; Kite, A Gilead Company; NovImmune SA; Pfizer; Servier Pharmaceuticals LLC; Trillium Therapeutics Inc.; and TrovaGene, Inc. Research funding goes to institution.

Co-Chair/Planner
Gail J. Roboz, MD
William S. Paley Professor of Medicine
Director, Clinical and Translational Leukemia Programs
Weill Cornell Medicine
The New York Presbyterian Hospital
New York, New York

Gail J. Roboz, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie; Amgen Inc.; Argenx; AstraZeneca; bluebird bio, Inc.; Blueprint Medicines; Bristol Myers Squibb; Caribou Biosciences; Celgene Corporation; Daiichi Sankyo, Inc.; Ellipses Pharma; F. Hoffmann-La Roche AG; GlaxoSmithKline; Janssen Pharmaceuticals, Inc; Jasper Therapeutics, Inc.; Jazz Pharmaceuticals, Inc.; Molecular Partners; Novartis Pharmaceuticals Corporation; Pfizer; Syndax Pharmaceuticals Inc.; Takeda Pharmaceutical Company Limited (IRC Chair); and Telix Pharma.
Grant/Research Support from Janssen Pharmaceuticals, Inc.

All of the relevant financial relationships listed have been mitigated.

Planning Committee and Content/Peer Reviewers

The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, and PVI, PeerView Institute for Medical Education, our educational partner, do not have any relevant financial relationship(s) to disclose with ineligible companies unless listed below.

Disclosure of Unlabeled Use

This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

In order to receive credit, learners must participate in the entire CE activity. A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 70% or higher is needed to obtain MOC/CC credit (75% is required for ABS).

For nurses, the post-test and evaluation are required in their entirety and a score of 70% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) contact hours.

For pharmacists, upon receipt of the completed activity evaluation, you will receive an email from email@email.peerviewpress.com within 2 weeks. MLI will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and DOB (MM/DD). Within 6 weeks, you can view your participation record at the NABP website: https://nabp.pharmacy/.

About This CME/MOC/NCPD/CPE Activity

PVI, PeerView Institute for Medical Education, and Medical Learning Institute, Inc. are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Medical Learning Institute, Inc.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

Copyright © 2000-2023, PeerView

September 06, 2023
Credits: 1.0 CME / MOC / NCPD / CPE
Medical Learning Institute, Inc.
Setting New Expectations in Multiple Myeloma: Guidance on BCMA CAR-T & Antibody Options to Enhance Patient Care

Setting New Expectations in Multiple Myeloma: Guidance on BCMA CAR-T & Antibody Options to Enhance Patient Care

Start

Setting New Expectations in Multiple Myeloma: Guidance on BCMA CAR-T & Antibody Options to Enhance Patient Care

Media: Enduring Material
Activity Release Date: September 7, 2023
Activity Expiration Date: October 6, 2024
Time to Complete Activity: 60 minutes

Activity Description

Find out if you are prepared to select the best care for your patients with multiple myeloma (MM) in this activity based on a symposium that was recorded at the Society of Hematologic Oncology’s 11th Annual Meeting. Join the MM experts as they workshop real-world issues of integrating anti-BCMA options into MM care while also providing solutions designed to speed up the integration of CAR-T and antibody platforms into patient management. Each interactive discussion will cover BCMA CAR-T platforms, antibody-drug conjugates, and BCMA and non-BCMA bispecifics, and feature supporting evidence on earlier use of cellular therapy; the role of CAR-T and bispecific antibodies in early and later relapse; and next steps for the sequential use of “off-the-shelf” immunotherapy. Access this video activity today and see if you are prepared to enhance patient care with the latest BCMA and non-BCMA treatment options!

Target Audience

This activity has been designed to meet the educational needs of hematologist-oncologists, hematologists, nurses, pharmacists, advanced practice clinicians (including hematology-oncology NPs and PAs), and other clinicians involved in the management of multiple myeloma.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Describe the mechanisms of action and latest clinical evidence supporting the use of established and emerging BCMA-targeting platforms, including bispecific antibodies and CAR-T therapy, across several lines of therapy in MM
  • Select anti-BCMA options when developing personalized treatment plans for MM based on patient preference, disease prognosis, and functional status, among other considerations
  • Manage practical considerations associated with BCMA therapy, including planning for referral to specialized care, consideration of off-the-shelf therapy, safety, patient education, and coordination of care

Accreditation, Support, and Credit

JAP In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by independent medical educational grants from GSK, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC and, Regeneron Pharmaceuticals, Inc.

Physician Continuing Medical Education

Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nursing Continuing Professional Development

Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.

Continuing Pharmacy Education

Medical Learning Institute, Inc. designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA0007322-0000-23-090-H01-P
Type of Activity: Application

Faculty Disclosures

Co-Chair/Planner
Sagar Lonial, MD, FACP
Chair and Professor
Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Chief Medical Officer
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

Sagar Lonial, MD, FACP, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Amgen Inc.; Bristol Myers Squibb; Celgene Corporation; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; Pfizer; and Takeda Pharmaceutical Company Limited.
Grant/Research Support from Bristol Myers Squibb; Janssen Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; and Takeda Pharmaceutical Company Limited.
Stock Shareholder in TG Therapeutics.

Co-Chair/Planner
Krina Patel, MD, MSc
Associate Professor, Department of Lymphoma/Myeloma
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas

Krina Patel, MD, MSc, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie; AstraZeneca; Bristol Myers Squibb; Celgene Corporation; Curio Bioscience; Janssen Pharmaceuticals, Inc.; Karyopharm; Legend Biotech; Merck & Co., Inc.; Oncopeptides; Pfizer; and Precision BioSciences, Inc.
Grant/Research Support from AbbVie; Allogene Therapeutics, Inc.; Arcellx; Bristol Myers Squibb; Celgene Corporation; Cellectis; Janssen Pharmaceuticals, Inc.; Nektar Therapeutic; Poseida Therapeutics; Precision BioSciences, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.

All of the relevant financial relationships listed have been mitigated.

Planning Committee and Content/Peer Reviewers

The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, and PVI, PeerView Institute for Medical Education, our educational partner, do not have any relevant financial relationship(s) to disclose with ineligible companies unless listed below.

Disclosure of Unlabeled Use

This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

In order to receive credit, learners must participate in the entire CE activity. A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 70% or higher is needed to obtain MOC/CC credit (75% is required for ABS).

For nurses, the post-test and evaluation are required in their entirety and a score of 70% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) contact hours.

For pharmacists, upon receipt of the completed activity evaluation, you will receive an email from email@email.peerviewpress.com within 2 weeks. MLI will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and DOB (MM/DD). Within 6 weeks, you can view your participation record at the NABP website: https://nabp.pharmacy/.

About This CME/MOC/NCPD/CPE Activity

PVI, PeerView Institute for Medical Education, and Medical Learning Institute, Inc. are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Medical Learning Institute, Inc.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

Copyright © 2000-2023, PeerView

Setting New Expectations in Multiple Myeloma: Guidance on BCMA CAR-T & Antibody Options to Enhance Patient Care

Media: Enduring Material
Activity Release Date: September 7, 2023
Activity Expiration Date: October 6, 2024
Time to Complete Activity: 60 minutes

Activity Description

Find out if you are prepared to select the best care for your patients with multiple myeloma (MM) in this activity based on a symposium that was recorded at the Society of Hematologic Oncology’s 11th Annual Meeting. Join the MM experts as they workshop real-world issues of integrating anti-BCMA options into MM care while also providing solutions designed to speed up the integration of CAR-T and antibody platforms into patient management. Each interactive discussion will cover BCMA CAR-T platforms, antibody-drug conjugates, and BCMA and non-BCMA bispecifics, and feature supporting evidence on earlier use of cellular therapy; the role of CAR-T and bispecific antibodies in early and later relapse; and next steps for the sequential use of “off-the-shelf” immunotherapy. Access this video activity today and see if you are prepared to enhance patient care with the latest BCMA and non-BCMA treatment options!

Target Audience

This activity has been designed to meet the educational needs of hematologist-oncologists, hematologists, nurses, pharmacists, advanced practice clinicians (including hematology-oncology NPs and PAs), and other clinicians involved in the management of multiple myeloma.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Describe the mechanisms of action and latest clinical evidence supporting the use of established and emerging BCMA-targeting platforms, including bispecific antibodies and CAR-T therapy, across several lines of therapy in MM
  • Select anti-BCMA options when developing personalized treatment plans for MM based on patient preference, disease prognosis, and functional status, among other considerations
  • Manage practical considerations associated with BCMA therapy, including planning for referral to specialized care, consideration of off-the-shelf therapy, safety, patient education, and coordination of care

Accreditation, Support, and Credit

JAP In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by independent medical educational grants from GSK, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC and, Regeneron Pharmaceuticals, Inc.

Physician Continuing Medical Education

Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nursing Continuing Professional Development

Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.

Continuing Pharmacy Education

Medical Learning Institute, Inc. designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA0007322-0000-23-090-H01-P
Type of Activity: Application

Faculty Disclosures

Co-Chair/Planner
Sagar Lonial, MD, FACP
Chair and Professor
Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Chief Medical Officer
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

Sagar Lonial, MD, FACP, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Amgen Inc.; Bristol Myers Squibb; Celgene Corporation; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; Pfizer; and Takeda Pharmaceutical Company Limited.
Grant/Research Support from Bristol Myers Squibb; Janssen Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; and Takeda Pharmaceutical Company Limited.
Stock Shareholder in TG Therapeutics.

Co-Chair/Planner
Krina Patel, MD, MSc
Associate Professor, Department of Lymphoma/Myeloma
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas

Krina Patel, MD, MSc, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie; AstraZeneca; Bristol Myers Squibb; Celgene Corporation; Curio Bioscience; Janssen Pharmaceuticals, Inc.; Karyopharm; Legend Biotech; Merck & Co., Inc.; Oncopeptides; Pfizer; and Precision BioSciences, Inc.
Grant/Research Support from AbbVie; Allogene Therapeutics, Inc.; Arcellx; Bristol Myers Squibb; Celgene Corporation; Cellectis; Janssen Pharmaceuticals, Inc.; Nektar Therapeutic; Poseida Therapeutics; Precision BioSciences, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.

All of the relevant financial relationships listed have been mitigated.

Planning Committee and Content/Peer Reviewers

The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, and PVI, PeerView Institute for Medical Education, our educational partner, do not have any relevant financial relationship(s) to disclose with ineligible companies unless listed below.

Disclosure of Unlabeled Use

This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

In order to receive credit, learners must participate in the entire CE activity. A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 70% or higher is needed to obtain MOC/CC credit (75% is required for ABS).

For nurses, the post-test and evaluation are required in their entirety and a score of 70% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) contact hours.

For pharmacists, upon receipt of the completed activity evaluation, you will receive an email from email@email.peerviewpress.com within 2 weeks. MLI will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and DOB (MM/DD). Within 6 weeks, you can view your participation record at the NABP website: https://nabp.pharmacy/.

About This CME/MOC/NCPD/CPE Activity

PVI, PeerView Institute for Medical Education, and Medical Learning Institute, Inc. are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Medical Learning Institute, Inc.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

Copyright © 2000-2023, PeerView

September 06, 2023
Credits: 0.75 CME / MOC / NCPD / CPE / CECH
PVI, PeerView Institute for Medical Education
Road Map to Re-Engagement: A Visual Guide to Overcoming Individual and Systemic Barriers to HIV Care and Treatment

Road Map to Re-Engagement: A Visual Guide to Overcoming Individual and Systemic Barriers to HIV Care and Treatment

Start

Road Map to Re-Engagement: A Visual Guide to Overcoming Individual and Systemic Barriers to HIV Care and Treatment

Media: Enduring Material
Activity Release Date: August 3, 2023
Activity Expiration Date: August 2, 2024
Time to Complete Activity:

  • 45 minutes

Activity Description

In this activity, an expert discusses the factors that contribute to people living with HIV (PLWH) falling out of care, the barriers associated with different strategies for re-engaging PLWH, and individualized plans that can be used for re-engaging PLWH back into care.

Target Audience

This activity has been designed to meet the educational needs of primary care providers, HIV care providers, infectious disease providers, HIV workforce professionals, and other clinicians involved in the care of patients with HIV.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Identify individual and structural factors that contribute to PLWH falling out of care
  • Discuss methodologies, benefits, and limitations associated with different strategies for re-engaging PLWH who are out of care
  • Employ individualized and comprehensive plans to successfully re-engage PLWH in care

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Babafemi O. Taiwo, MBBS
Chief of Infectious Diseases in the Department of Medicine
Gene Stollerman Professor of Medicine
Professor of Medicine (Infectious Diseases)
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Babafemi O. Taiwo, MBBS, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Gilead Sciences, Inc.; Johnson & Johnson; Merck & Co., Inc.; and ViiV Healthcare.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.


Accreditation, Support, and Credit

JAP In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthHIV. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Partners

This activity has been developed in partnership with HealthHIV

Support

This activity is supported by an educational grant from Gilead Sciences, Inc.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 0.75 contact hour(s) and no contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 0.75 contact hours (0.075 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-9999-23-047-H02-P
Type of Activity:

Health Education Specialists

Sponsored by PVI, PeerView Institute for Medical Education, a designated provider of continuing education contact hours (CECH) in health education by the National Commission for Health Education Credentialing, Inc. This program is designated for Certified Health Education Specialists (CHES®) and/or Master Certified Health Education Specialists (MCHES®) to receive up to 0.75 total Category 1 continuing education contact hours. Maximum advanced-level continuing education contact hours are 0.0. Continuing Competency credits available are 0.0.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD/CPE/CECH Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2023, PeerView

Road Map to Re-Engagement: A Visual Guide to Overcoming Individual and Systemic Barriers to HIV Care and Treatment

Media: Enduring Material
Activity Release Date: August 3, 2023
Activity Expiration Date: August 2, 2024
Time to Complete Activity:

  • 45 minutes

Activity Description

In this activity, an expert discusses the factors that contribute to people living with HIV (PLWH) falling out of care, the barriers associated with different strategies for re-engaging PLWH, and individualized plans that can be used for re-engaging PLWH back into care.

Target Audience

This activity has been designed to meet the educational needs of primary care providers, HIV care providers, infectious disease providers, HIV workforce professionals, and other clinicians involved in the care of patients with HIV.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Identify individual and structural factors that contribute to PLWH falling out of care
  • Discuss methodologies, benefits, and limitations associated with different strategies for re-engaging PLWH who are out of care
  • Employ individualized and comprehensive plans to successfully re-engage PLWH in care

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Babafemi O. Taiwo, MBBS
Chief of Infectious Diseases in the Department of Medicine
Gene Stollerman Professor of Medicine
Professor of Medicine (Infectious Diseases)
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Babafemi O. Taiwo, MBBS, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Gilead Sciences, Inc.; Johnson & Johnson; Merck & Co., Inc.; and ViiV Healthcare.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.


Accreditation, Support, and Credit

JAP In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthHIV. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Partners

This activity has been developed in partnership with HealthHIV

Support

This activity is supported by an educational grant from Gilead Sciences, Inc.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 0.75 contact hour(s) and no contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 0.75 contact hours (0.075 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-9999-23-047-H02-P
Type of Activity:

Health Education Specialists

Sponsored by PVI, PeerView Institute for Medical Education, a designated provider of continuing education contact hours (CECH) in health education by the National Commission for Health Education Credentialing, Inc. This program is designated for Certified Health Education Specialists (CHES®) and/or Master Certified Health Education Specialists (MCHES®) to receive up to 0.75 total Category 1 continuing education contact hours. Maximum advanced-level continuing education contact hours are 0.0. Continuing Competency credits available are 0.0.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD/CPE/CECH Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2023, PeerView

August 02, 2023
Credits: 1.0 CME / MOC / CC / NCPD / CPE / IPCE
PVI, PeerView Institute for Medical Education
Taking Direction From Biomarkers and Prognostic Factors in CLL: Interprofessional Strategies for Addressing Challenges With Continuous BTKi Therapy

Taking Direction From Biomarkers and Prognostic Factors in CLL: Interprofessional Strategies for Addressing Challenges With Continuous BTKi Therapy

Start

Taking Direction From Biomarkers and Prognostic Factors in CLL: Interprofessional Strategies for Addressing Challenges With Continuous BTKi Therapy

Media: Enduring Material
Activity Release Date: August 2, 2023
Activity Expiration Date: August 1, 2024
Time to Complete Activity: 60 minutes

Activity Description

Learn how CLL expert Jennifer Woyach, MD, employs patient treatment history, prognostic information, and other clinically relevant factors to develop comprehensive treatment plans for her patients and get up to date on the latest evidence with BTK inhibitors for CLL by participating in this video activity. Dr. Woyach will focus on enhancing your understanding of the mechanistic, selectivity, and safety differences between covalent and non-covalent BTK inhibitors (BTKi) and BCL2 inhibitors (BCL2i), the mechanisms of intolerance and BTK resistance, and how BTKi fit into personalized treatment plans informed by the use of validated techniques such as next-generation sequencing, FISH, and karyotype testing. Learners will also be exposed to resources from the CLL Society that can be used to help educate patients on the latest therapeutic advances in customized CLL care.

Target Audience

This activity has been designed to meet the educational needs of hematologists, oncologists, hematology-oncologists, pathologists, nurses, pharmacists, and other clinicians involved in the care of patients with CLL.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Summarize the mechanistic, selectivity, and safety differences among covalent and non-covalent BTKi, including off-target effects, therapeutic intolerance, and mechanisms of BTK resistance
  • Cite validated techniques, including next-generation sequencing, to identify prognostic and predictive markers such as del(17p)/TP53, BTK mutations, and minimal residual disease status to inform treatment decisions
  • Develop team-based management strategies that include patient treatment history, prognostic information, and other clinically relevant factors
  • Implement team-based strategies to educate patients on their prognosis, facilitate clinical trial enrollment, and address dosing and safety considerations when using BTKi strategies

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Jennifer Woyach, MD
Professor of Internal Medicine
Division of Hematology
The Ohio State University
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
Columbus, Ohio

Jennifer Woyach, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for ArQule, Inc.; AstraZeneca; BeiGene; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Loxo Oncology; Newave Pharmaceutical Inc; and Pharmacyclics LLC.
Grant/Research Support from AstraZeneca; Karyopharm Therapeutics; Loxo Oncology; MingSight Pharmaceuticals, Inc.; MorphoSys US Inc.; Schrödinger, Inc.; and Verastem Oncology.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

JAP In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and CLL Society. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by an educational grant from Merck & Co., Inc.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Continuing Certification Statement

ABPath The activity titled “Taking Direction From Biomarkers and Prognostic Factors in CLL: Interprofessional Strategies for Addressing Challenges With Continuous BTKi Therapy” has been registered to offer 1.0 Lifelong Learning credit in the American Board of Pathology’s (ABPath) Continuing Certification program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABPath Continuing Certification credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-9999-23-054-H01-P
Type of Activity: Application

Interprofessional Continuing Education (IPCE) Statement

IPCE This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/CC/NCPD/CPE/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2023, PeerView

Taking Direction From Biomarkers and Prognostic Factors in CLL: Interprofessional Strategies for Addressing Challenges With Continuous BTKi Therapy

Media: Enduring Material
Activity Release Date: August 2, 2023
Activity Expiration Date: August 1, 2024
Time to Complete Activity: 60 minutes

Activity Description

Learn how CLL expert Jennifer Woyach, MD, employs patient treatment history, prognostic information, and other clinically relevant factors to develop comprehensive treatment plans for her patients and get up to date on the latest evidence with BTK inhibitors for CLL by participating in this video activity. Dr. Woyach will focus on enhancing your understanding of the mechanistic, selectivity, and safety differences between covalent and non-covalent BTK inhibitors (BTKi) and BCL2 inhibitors (BCL2i), the mechanisms of intolerance and BTK resistance, and how BTKi fit into personalized treatment plans informed by the use of validated techniques such as next-generation sequencing, FISH, and karyotype testing. Learners will also be exposed to resources from the CLL Society that can be used to help educate patients on the latest therapeutic advances in customized CLL care.

Target Audience

This activity has been designed to meet the educational needs of hematologists, oncologists, hematology-oncologists, pathologists, nurses, pharmacists, and other clinicians involved in the care of patients with CLL.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Summarize the mechanistic, selectivity, and safety differences among covalent and non-covalent BTKi, including off-target effects, therapeutic intolerance, and mechanisms of BTK resistance
  • Cite validated techniques, including next-generation sequencing, to identify prognostic and predictive markers such as del(17p)/TP53, BTK mutations, and minimal residual disease status to inform treatment decisions
  • Develop team-based management strategies that include patient treatment history, prognostic information, and other clinically relevant factors
  • Implement team-based strategies to educate patients on their prognosis, facilitate clinical trial enrollment, and address dosing and safety considerations when using BTKi strategies

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Jennifer Woyach, MD
Professor of Internal Medicine
Division of Hematology
The Ohio State University
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
Columbus, Ohio

Jennifer Woyach, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for ArQule, Inc.; AstraZeneca; BeiGene; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Loxo Oncology; Newave Pharmaceutical Inc; and Pharmacyclics LLC.
Grant/Research Support from AstraZeneca; Karyopharm Therapeutics; Loxo Oncology; MingSight Pharmaceuticals, Inc.; MorphoSys US Inc.; Schrödinger, Inc.; and Verastem Oncology.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

JAP In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and CLL Society. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by an educational grant from Merck & Co., Inc.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Continuing Certification Statement

ABPath The activity titled “Taking Direction From Biomarkers and Prognostic Factors in CLL: Interprofessional Strategies for Addressing Challenges With Continuous BTKi Therapy” has been registered to offer 1.0 Lifelong Learning credit in the American Board of Pathology’s (ABPath) Continuing Certification program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABPath Continuing Certification credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-9999-23-054-H01-P
Type of Activity: Application

Interprofessional Continuing Education (IPCE) Statement

IPCE This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/CC/NCPD/CPE/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2023, PeerView

August 01, 2023
Credits: 0.75 CME / MOC / NCPD / CPE / CECH
PVI, PeerView Institute for Medical Education
Retaining and Re-Engaging People Living With HIV in Care: A Unique Look at Challenges and Opportunities From the Perspective of the Patient, Navigator, and Provider

Retaining and Re-Engaging People Living With HIV in Care: A Unique Look at Challenges and Opportunities From the Perspective of the Patient, Navigator, and Provider

Start

Retaining and Re-Engaging People Living With HIV in Care: A Unique Look at Challenges and Opportunities From the Perspective of the Patient, Navigator, and Provider

Media: Enduring Material
Activity Release Date: June 29, 2023
Activity Expiration Date: June 28, 2024
Time to Complete Activity: 45 minutes

Activity Description

In this activity, an expert provider, navigator, and two patients explore the factors that contribute to people living with HIV (PLWH) falling out of care and different strategies that can be used for re-engaging PLWH back into the HIV care continuum.

Target Audience

This activity has been designed to meet the educational needs of healthcare professionals who treat, care for, and/or support people living with HIV.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Identify individual and structural factors that contribute to PLWH falling out of care
  • Discuss methodologies, benefits, and limitations associated with different strategies for re-engaging PLWH who are out of care
  • Employ individualized and comprehensive plans to successfully re-engage PLWH in care

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Allison Agwu, MD, ScM, FAAP, FIDSA
Professor of Pediatrics and Internal Medicine
Division of Infectious Diseases
Program Director, Pediatric Adolescent Young Adult HIV/AIDS Program
Medical Director, Accessing Care Early (ACE) Clinic
Johns Hopkins University School of Medicine
Baltimore, Maryland

Allison Agwu, MD, ScM, FAAP, FIDSA, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Gilead Sciences, Inc.; Merck & Co., Inc.; and ViiV Healthcare.
Grant/Research Support from Gilead Sciences, Inc. and Merck & Co., Inc.

Faculty/Planner
Nara Lee, LICSW
Social Work & Clinical Services Manager
HIV Prevention and Treatment Services
Special Immunology Services
Children’s National Hospital
Washington, DC

Nara Lee, LICSW, has no financial interests/relationships or affiliations in relation to this activity.

Patient/Planner
David Martin
Patient/Advocate

David Martin has no financial interests/relationships or affiliations in relation to this activity.

Patient/Planner
Shawnte' Spriggs
Patient/Advocate

Shawnte' Spriggs has no financial interests/relationships or affiliations in relation to this activity.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

JAP In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthHIV. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by an educational grant from Gilead Sciences, Inc.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 0.75 contact hour(s) and no contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 0.75 contact hours (0.075 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-9999-23-046-H02-P
Type of Activity: Knowledge

Health Education Specialists

Sponsored by PVI, PeerView Institute for Medical Education, a designated provider of continuing education contact hours (CECH) in health education by the National Commission for Health Education Credentialing, Inc. This program is designated for Certified Health Education Specialists (CHES®) and/or Master Certified Health Education Specialists (MCHES®) to receive up to 0.75 total Category 1 continuing education contact hours. Maximum advanced-level continuing education contact hours are 0.0. Continuing Competency credits available are 0.0.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD/CPE/CECH Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2023, PeerView

Retaining and Re-Engaging People Living With HIV in Care: A Unique Look at Challenges and Opportunities From the Perspective of the Patient, Navigator, and Provider

Media: Enduring Material
Activity Release Date: June 29, 2023
Activity Expiration Date: June 28, 2024
Time to Complete Activity: 45 minutes

Activity Description

In this activity, an expert provider, navigator, and two patients explore the factors that contribute to people living with HIV (PLWH) falling out of care and different strategies that can be used for re-engaging PLWH back into the HIV care continuum.

Target Audience

This activity has been designed to meet the educational needs of healthcare professionals who treat, care for, and/or support people living with HIV.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Identify individual and structural factors that contribute to PLWH falling out of care
  • Discuss methodologies, benefits, and limitations associated with different strategies for re-engaging PLWH who are out of care
  • Employ individualized and comprehensive plans to successfully re-engage PLWH in care

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Allison Agwu, MD, ScM, FAAP, FIDSA
Professor of Pediatrics and Internal Medicine
Division of Infectious Diseases
Program Director, Pediatric Adolescent Young Adult HIV/AIDS Program
Medical Director, Accessing Care Early (ACE) Clinic
Johns Hopkins University School of Medicine
Baltimore, Maryland

Allison Agwu, MD, ScM, FAAP, FIDSA, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Gilead Sciences, Inc.; Merck & Co., Inc.; and ViiV Healthcare.
Grant/Research Support from Gilead Sciences, Inc. and Merck & Co., Inc.

Faculty/Planner
Nara Lee, LICSW
Social Work & Clinical Services Manager
HIV Prevention and Treatment Services
Special Immunology Services
Children’s National Hospital
Washington, DC

Nara Lee, LICSW, has no financial interests/relationships or affiliations in relation to this activity.

Patient/Planner
David Martin
Patient/Advocate

David Martin has no financial interests/relationships or affiliations in relation to this activity.

Patient/Planner
Shawnte' Spriggs
Patient/Advocate

Shawnte' Spriggs has no financial interests/relationships or affiliations in relation to this activity.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

JAP In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthHIV. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by an educational grant from Gilead Sciences, Inc.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 0.75 contact hour(s) and no contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 0.75 contact hours (0.075 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-9999-23-046-H02-P
Type of Activity: Knowledge

Health Education Specialists

Sponsored by PVI, PeerView Institute for Medical Education, a designated provider of continuing education contact hours (CECH) in health education by the National Commission for Health Education Credentialing, Inc. This program is designated for Certified Health Education Specialists (CHES®) and/or Master Certified Health Education Specialists (MCHES®) to receive up to 0.75 total Category 1 continuing education contact hours. Maximum advanced-level continuing education contact hours are 0.0. Continuing Competency credits available are 0.0.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD/CPE/CECH Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2023, PeerView

June 28, 2023

Pages